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Abstrakt 
Die Umwandlung in wasserlösliche Verbindungen, die renal ausgeschieden werden können, ist 
ein grundlegendes Prinzip im Abbau von Fremdstoffen. Hierbei unterscheidet man Phase-I- und 
Phase-II-Reaktionen. Die Aktivität vieler Phase-I- und Phase-II-Enzyme ist genetisch beeinflusst 
und kann starke interindividuelle Unterschiede im Metabolismus von Fremdstoffen verursachen 
und dadurch das Krebsrisiko und das Risiko für Arzneimittelnebenwirkungen beeinflussen. Die 
Häufigkeitsverteilungen der Allele der Gene, die Phase-I- und Phase-II-Enzyme kodieren, zeigen 
eine große interethnische Varianz. Die Polymorphismen dieser Enzyme wurden bisher jedoch 
noch nicht in der größten slawischen Volksgruppe, der russischen, untersucht. An der 
vorliegenden Studie nahm eine Gruppe von 325 Personen russischer Abstammung teil - gesunde 
Probanden bzw. Patienten, die nicht an einer malignen Erkrankung litten. Die Polymorphismen 
von zwei Enzymen der Phase I, CYP1A1 und CYP2D6, und von einem Enzym der Phase II, 
NAT2, wurden mittels PCR-RFLP-Genotypisierung und Real-time-PCR-Verfahren komplett 
untersucht. Die Häufigkeit der CYP1A1 Allele mit hoher Aktivität, CYP1A1*2A und 
CYP1A1*2B, betrug 4,6% (3,1%-6,5%) bzw. 5,1% (3,5%-7,1%). Die Häufigkeiten der 
genetischen Varianten von CYP1A1 waren: m1 (3801T>C) - 9,8% (95% Vertrauensbereich, 
7,7%-12,4%), m2 (2455A>G) - 5,0% (95% VB, 3,5%-7,1%), m4 (2453C>A) - 2,5% (1,4%-
4,0%), m5 (-4335G>A) - 25,8% (22,5%-29,4%), m6 (-3219C>T) - 6,0% (4,3%-8,1%), und m7 (-
3229G>A) - 2,9% (1,8%-4,5%). Die Mutation m3, die bisher nur bei Afrikaner gefunden wurde, 
konnten wir nicht nachweisen. 5,9% (3,5%-9,2%) aller Probanden waren CYP2D6 Langsam-
Metabolisierer und 3,4% (1,7%-6,3%) wurden als Ultraschnell-Metabolisierer identifiziert 
(CYP2D6*1x1/*1). Bei der Genotypisierung von acht verschiedenen Punktmutationen im NAT2-
Gen ergab sich für 59,7% (54,1%-65,1%) der Studienteilnehmer ein Genotyp, der mit einer 
Langsam-Acetylierer-Status einhergeht. 34,7% (29,6%-40,2%) der Probanden hatten ein und 
5,6% (3,3%-8,6%) zwei für die Schnellacetylierung kodierende Allele. Die Allelverteilung der 
für die wichtigsten Enzyme im Arzneimittelstoffwechsel kodierenden Gene ist bei Russen 
ähnlich wie bei anderen Kaukasiern. Es kann deshalb erwartet werden, dass die genetisch-
bedingten Unterschiede in der Wirksamkeit und im Auftreten von Arzneimittelnebenwirkungen 
in der russischen Bevölkerung vergleichbar sind mit denen in anderen europäischen 
Populationen. 
Schlagworte: Cytochrom P450, CYP1A1, CYP2D6, NAT2, Russische Bevölkerung, Genotyp 
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Abstract 
The basic principle of drug and xenobiotic metabolism in the body is to make them more water 
soluble and thus more readily excreted in the urine. Genetic polymorphisms of phases I and II 
xenobiotic transformation reactions are known to contribute considerably to interindividual 
variations in the metabolism of numerous drugs and xenobiotics and to associate with altered 
risk of adverse drug reactions and some cancers. The frequency of functionally important 
mutations and alleles of genes coding for xenobiotic metabolizing enzymes shows a wide ethnic 
variation. However, little is known of the frequency distribution of the major allelic variants in 
the Russian population. In this study we investigated 325 individuals of Russian origin, who 
were healthy volunteers or patients without malignant diseases. Our study included the complete 
investigation of two enzymes of phase I, CYP1A1 and CYP2D6, and one phase II enzyme, 
NAT2, using PCR-RFLP genotyping and LightCycler method. The frequencies of the CYP1A1 
high-activity alleles, CYP1A1*2A and CYP1A1*2B, were 4.6% (3.1%-6.5%) and 5.1% (3.5%-
7.1%), respectively. The mutations m1 (3801T>C), m2 (2455A>G), m4 (2453C>A), m5 (-
4335G>A), m6 (-3219C>T), and m7 (-3229G>A) of CYP1A1 occurred in 9.8% (95% confidence 
interval, 7.7%-12.4%), 5.0% (95% C. I., 3.5%-7.1%), 2.5% (1.4%-4.0%), 25.8% (22.5%-29.4%), 
6.0% (4.3%-8.1%), and 2.9% (1.8%-4.5%) of alleles, respectively. We did not find the m3 
mutation, which has only been detected in Africans up to now. 5.9% (3.5%-9.2%) of all subjects 
were CYP2D6 poor metabolizers, whereas 3.4% (1.7%-6.3%) were identified as ultra-rapid 
metabolizers (CYP2D6*1x1/*1). Genotyping eight different single nucleotide polymorphisms in 
the NAT2 gene provided a genotype associated with slow acetylation in 59.7% (54.1%-65.1%) of 
individuals, 34.7% (29.6%-40.2%) of participants carried at least one allele encoding rapid 
acetylation, and 5.6% (3.3%-8.6%) were homozygous for the rapid-acetylation allele (wild-type 
allele *4 or mutant allele *12A). The overview of allele distribution of the important drug and 
xenobiotic metabolizing enzymes among Russians shows that the allele frequency is similar to 
that of other Caucasians. Therefore it may be expected that drug side effects and efficacy 
problems due to an individual's genetic background are similar compared to those in other 
European populations. 
Keywords: Cytochrome P450, CYP1A1, CYP2D6, NAT2, Russians, Genotype 
 5
CONTENTS 
1 Introduction ...........................................................................................................................9 
1.1 Cytochrome P450 enzyme system................................................................................12 
1.1.1 Evolution of CYP450 genes .........................................................................................14 
1.1.2 Cytochrome P450 1A1 (CYP1A1) ...............................................................................15 
1.1.3 Cytochrome P450 2D6 (CYP2D6) ...............................................................................17 
1.2 Phase II enzyme reaction ..............................................................................................18 
1.2.1 Arylamine N-acetyltransferase 2 ..................................................................................18 
1.3 The purpose of the work ...............................................................................................22 
2 Materials and methods........................................................................................................23 
2.1 Patients..........................................................................................................................23 
2.2 Materials .......................................................................................................................24 
2.2.1 Chemicals .....................................................................................................................24 
2.2.2 Equipment.....................................................................................................................25 
2.3 Methods ........................................................................................................................25 
2.3.1 DNA extraction.............................................................................................................25 
2.3.2 Genotyping methods.....................................................................................................26 
2.3.2.1 Polymerase chain reaction/ restriction fragment length polymorphism (PCR-RFLP) .26 
2.3.2.2 LightCycler assay .........................................................................................................27 
2.3.2.3 Genotyping of CYP1A1 mutations................................................................................28 
2.3.2.4 Genotyping of CYP2D6 mutations ...............................................................................31 
2.3.2.5 Genotyping of NAT2 mutations ....................................................................................38 
2.3.2.6 Identification of NAT2 genotypes by continuous monitoring of fluorogenic 
hybridization probes .....................................................................................................42 
2.4 Statistical analysis.........................................................................................................45 
3 Results ..................................................................................................................................46 
3.1 Frequencies of CYP1A1 point mutations and alleles....................................................46 
3.2 Genotype frequencies of CYP1A1 ................................................................................47 
3.3 Allele frequencies of CYP2D6......................................................................................48 
 6
3.4 Frequencies of CYP2D6 genotypes ..............................................................................48 
3.5 Frequencies of CYP2D6 genotypes, according to gender ............................................50 
3.6 Frequencies of CYP2D6 genotypes, according to age..................................................50 
3.7 Frequencies of NAT2 point mutations and alleles ........................................................51 
3.8 Frequencies of NAT2 genotypes ...................................................................................52 
3.9 Identification of N-acetyltransferase 2 genotypes by continuous monitoring of 
fluorogenic hybridization probes..................................................................................53 
4 Discussion.............................................................................................................................56 
4.1 Interethnic variability of enzymes of phases I and II ...................................................56 
4.1.1 Genotype frequencies of CYP1A1 ................................................................................56 
4.1.2 Genotype frequencies of CYP2D6................................................................................57 
4.1.3 Genotype frequencies of NAT2.....................................................................................58 
4.2 Individual pharmacotherapy adjusted to genotype .......................................................59 
4.2.1 Genetic susceptibility to adverse drug reactions ..........................................................61 
1.1.4 Impact of the CYP2D6 genotype on drug treatment.....................................................63 
1.1.5 Inhibition of cytochrome P450 .....................................................................................65 
4.2.2 Induction of cytochrome P450......................................................................................66 
4.2.3 Clinically relevant polymorphisms of NAT2 ................................................................66 
4.2.4 Pharmacogenetic studies and the practice of medicine ................................................67 
4.3 The role of polymorphisms of drug metabolizing enzymes in the occurrence of some 
kinds of cancer ..............................................................................................................68 
4.3.1 Genetic polymorphism of CYP1A1 and cancer susceptibility......................................69 
4.3.2 The influence of the CYP2D6 genotype on cancer susceptibility ................................70 
4.3.3 The role of N-acetyltransferase 2 in the predisposition to aromatic and heterocyclic 
amine-induced carcinogenesis ......................................................................................71 
4.3.4 Cancer susceptibility related to ethnicity or race..........................................................72 
5 Summary ..............................................................................................................................73 
6 Zusammenfassung...............................................................................................................75 
7 References ............................................................................................................................78 
Acknowledgements......................................................................................................................91 
 7
Eidesstattliche Erklärung...........................................................................................................92 
Lebenslauf ....................................................................................................................................92 
 
 8
Abbreviations 
bp  basepairs 
95% C.I. 95% confidence interval 
CYP1A1 cytochrome P450 1A1 (enzyme) 
CYP1A1 cytochrome P450 1A1 (gene) 
CYP2D6 cytochrome P450 2D6 (enzyme) 
CYP2D6 cytochrome P450 2D6 (gene) 
BSA bovine serum albumin 
dNTP deoxyribonucleotide triphosphate (dATP, dCTC, dGTP and dTTP) 
DME drug-metabolizing enzyme 
DMSO dimethylsulfoxide 
EM extensive metabolizer 
IM intermediate metabolizer 
NAT2 arylamine N-acetyltransferase 2 (enzyme) 
NAT2 arylamine N-acetyltransferase 2 (gene) 
nt nucleotide 
PAH polycyclic aromatic hydrocarbon 
PCR polymerase chain reaction 
PM poor metabolizer 
RFLP restriction fragment length polymorphism 
rpm rounds per minute 
Taq Thermus aquaticus 
U unit 
UM ultrarapid metabolizer 
wt wild type 
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1 Introduction 
All organisms are exposed constantly and unavoidably to foreign chemicals, or xenobiotics, 
which include both man-made and natural chemicals such as drugs, industrial chemicals, 
pesticides, pollutants, pyrolysis products in cooked food, alkaloids, secondary plant metabolites, 
and toxins produced by molds, plants and animals. The physical property that enables many 
xenobiotics to be absorbed through the skin, lungs, or gastrointestinal tract, namely their 
lipophilicity, is an obstacle to their elimination because lipophilic compounds can be readily 
reabsorbed. Consequently, the elimination of xenobiotics often depends on their conversion to 
water-soluble compounds by a process known as biotransformation, which is catalyzed by 
enzymes in the liver and other tissues. 
The activity of these enzymes varies broadly between individuals from absence to high activity 
and this variance can be responsible for adverse or toxic effects of drugs and xenobiotics or plays 
a key role in the etiopathology of several malignancies. Their enzymatic activities depend on 
hereditary polymorphisms of the genes which encode these enzymes. The frequency of 
functionally important mutations and alleles has been described in different populations 
revealing a broad ethnical variation. It is this aspect of ethnicity of foreign compound 
metabolism that the present work deals with taking the Russian population as an example. 
Genetic variability of clinically important biotransformation steps is investigated and compared 
to published data reflecting variability in other ethnic groups. It is expected that the knowledge 
of these variabilities in a specific population will improve drug treatment: firstly, by 
individualizing of drug dose according to the respective genetic trait of a patient; secondly, by 
reducing the incidence of side effects. Moreover, disease susceptibility has been shown to partly 
depend on the genetic make up of the enzymes which are involved in xenobiotic metabolism. For 
a better understanding of the results, the following chapters will explain the basic principles of 
the cytochrome P450 enzyme system and of the arylamine N-acetyltransferase, the main targets 
of the present work. 
An important consequence of biotransformation is that the physical properties of a xenobiotic are 
generally changed from those favoring absorption (lipophilicity) to those favoring excretion 
(hydrophilicity). A change in pharmacokinetic behavior is not the only result of xenobiotic 
biotransformation, but in some cases it is the most important one. Xenobiotics exert a variety of 
effects on biological systems. These may be beneficial – as in the case of drugs, or deleterious – 
as in the case of poisons. These effects are dependent on the physicochemical properties of the 
xenobiotic and often altered by biotransformation. Thus some drugs must undergo 
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biotransformation to be efficacious (because it is the metabolite of the drug, and not the drug 
itself, that exerts the pharmacological effect). Similarly, many xenobiotics must undergo 
biotransformation to exert their characteristic toxic or tumorogenic effects. Many chemicals 
would be considerably less toxic or tumorogenic if they were not converted to reactive 
metabolites by xenobiotic-biotransformation enzymes. In most cases, however, 
biotransformation terminates the effectiveness of a drug and lessens the toxicity of xenobiotics. 
Thus, enzymes catalyzing biotransformation reactions often determine the intensity and duration 
of the action of drugs and play a key role in chemical toxicity and chemical tumor genesis. 
The reactions catalyzed by xenobiotic-biotransforming enzymes are generally divided into two 
groups, called phase I and phase II (Table 1). Phase I reactions involve oxidation, hydrolysis and 
reduction. These reactions expose or introduce a functional group (-OH, -NH2, -SH or -COOH), 
and usually result in only a small increase in hydrophilicity. Phase II biotransformation 
reactions include glucuronidation, sulfation, acetylation, methylation, conjugation with 
glutathione (mercaptopuric acid synthesis) and conjugation with amino acids (such as glycine, 
taurine, and glutamic acid) (Pau86). 
 
Table 1: List of some drug metabolizing enzymes. 
Phase I reactions 
Oxidation Hydroxylation, N-oxidation, S-oxidation, N-
dealkylation, O-dealkylation, desamination, 
desulfation, oxidative dehalogenation 
Cytochrome P450-monooxigenases 
 Dehydration Alcohol dehydrogenase 
 dehydration of amines Monoaminoxidases 
 N-oxidation, S-oxidation Flavin monooxygenases 
Reduction Dehalogenisation of nitrogroups Cytochrome P450-monooxigenases 
Hydrolysis Hydrolysis of epoxides Epoxide hydrolases 
Oxidation of radicals Superoxide dismutases Others 
peroxidation glutathione peroxidases 
Phase II reactions 
Glucosylation UDP-glucuronosyltransferase 
sulfation sulfotransferases 
acetylation O-, N-acetyltransferases 
methylation O-, N-, S-methyltransferases 
Conjugation 
glutathione S-conjugation glutathione S-transferases 
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In these reactions, specific cofactors react with functional groups that are either present in 
xenobiotics or are introduced/exposed during phase I biotransformation. Most phase II 
biotransformation reactions result in a large increase in the hydrophilicity of the xenobiotic, 
hence they greatly promote the excretion of foreign chemicals. Phase II biotransformation of 
xenobiotics may or may not be preceded by phase I biotransformation. For example, morphine, 
heroine, and codeine are all converted to morphine-3-glucuronide. In the case of morphine, this 
metabolite is formed by direct conjugation with glucuronic acid. In the other two cases, however, 
conjugation with glucuronic acid is preceded by phase I biotransformation: hydrolysis 
(deacetylation) in the case of heroine, and O-demethylation (involving oxidation by cytochrome 
P450) in the case of codeine. In general, phase II biotransformation does not precede phase I 
biotransformation, although there are exceptions to this rule. For example, some sulfate steroids 
(including some steroid disulfates) are hydroxylated by cytochrome P450. 
Xenobiotic-biotransforming enzymes are widely distributed throughout the body, and are present 
in several subcellular compartments. The liver is the organ with the highest concentration of 
enzymes catalyzing biotransformation reactions. These enzymes are also located in the skin, 
lungs, nasal mucosa, eyes, and gastrointestinal tract. In the liver and in most other organs, they 
are located primarily in the endoplasmatic reticulum (microsomes) or in the soluble fraction of 
the cytoplasm (cytosol), with a smaller concentration in the mitochondria, nuclei, and lysosomes. 
By extracting and biotransforming xenobiotics absorbed from the gastrointestinal tract, the liver 
limits the systemic bioavailability of orally ingested xenobiotics, a process known as first pass 
elimination. In some cases, xenobiotic biotransformation in the intestine contributes significantly 
to the first pass elimination of foreign chemicals. For example, the oxidation of cyclosporin by 
cytochrome P450 and the conjugation of morphine with glucuronic acid in the small intestine 
limit the systemic bioavailability of these drugs. Under certain circumstances, the oxidation of 
ethanol to acetaldehyde in the gastric mucosa reduces the systemic bioavailability of alcohol. 
Some extrahepatic tissues contain high levels of xenobiotic-biotransforming enzymes, but their 
small size minimizes their overall contribution to the biotransformation of xenobiotics. For 
example, certain xenobiotic-biotransforming enzymes (such as cytochrome P450 enzymes, 
flavin-containing monooxygenases, glutathione S-transferases and carboxylesterases) are present 
in the nasal epithelium at levels that rival those found in the liver. The nasal epithelium plays an 
important role in the biotransformation of inhaled xenobiotics, including odorants, but it is 
quantitatively insignificant in the biotransformation of orally ingested xenobiotics (Bri93). 
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1.1 Cytochrome P450 enzyme system 
Among the phase I biotransformation enzymes, the cytochrome P450 system ranks first in terms 
of catalytic versatility and the sheer number of xenobiotics it detoxifies or activates to reactive 
intermediates (Gue87, Wat91). The highest concentration of P450 enzymes involved in xenobiotic 
biotransformation is found in the endoplasmatic reticulum of the liver (microsomes), but P450 
enzymes are present in almost all tissues. Microsomal P450 enzymes play a very important role 
in the regulation of the intensity and duration of drug action, in the detoxication of xenobiotics, 
and in the activation of xenobiotics to toxic and tumorogenic metabolites. In humans, about 40 
different microsomal and mitochondrial P450 enzymes play key role by catalyzing reactions in: 
 
• the metabolism of drugs, environmental pollutants and other xenobiotics; 
• the biosynthesis of steroid hormones; 
• the oxidation of unsaturated fatty acids to intracellular messengers; 
• the stereo- and regio-specific metabolism of fat-soluble vitamins. 
 
This underscores the catalytic flexibility of cytochrome P450. 
All P450 enzymes are heme-proteins. The heme iron in cytochrome P450 is usually in the ferric 
(Fe3+) state. When reduced to the ferrous (Fe2+) state, cytochrome P450 can bind ligands such as 
O2 and carbon monoxide (CO). The basis reaction catalyzed by cytochrome P450 is 
monooxygenation in which one atom of oxygen is incorporated into a substrate (RH); the other 
one is reduced to water with reducing equivalents derived from NADPH: 
 
Substrate (RH) + O2 +NADPH + H+ Product (ROH) + NADP+ +H2O  
Figure 1: P450-dependent oxygenation reaction.  
R – organic chemical that is transformed in the catalyzed reaction 
 
The liver microsomal P450 enzymes involved in xenobiotic biotransformation belong to three 
main P450 gene families, namely CYP1, CYP2 and CYP3. Liver microsomes also contain P450 
enzymes encoded by the CYP4 gene family, the substrates of which include several fatty acids 
and eicosanoids but relatively few xenobiotics.  
The level and activity of each P450 enzyme have been shown to vary from one individual to the 
next, due to environmental and genetic factors (Mey94, Shim94). Decreased P450 activity can 
result from (1) a genetic mutation that either blocks the synthesis of a P450 enzyme or leads to 
the synthesis of a catalytically compromised or inactive enzyme, (2) exposure to an 
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environmental factor (such as an infectious disease or a xenobiotic) that suppresses P450 enzyme 
expression, or (3) exposure to a xenobiotic that inhibits or inactivates a preexisting P450 
enzyme. By inhibiting cytochrome P450, one drug can impair the biotransformation of another, 
which can lead to an excessive pharmacological or toxicological response to the second drug. In 
this regard, inhibition of cytochrome P450 mimics the effects of a genetic deficiency in P450 
enzyme expression. Increased P450 enzyme activity can result from (1) gene duplication leading 
to overexpression of a P450 enzyme, (2) exposure to environmental factors, such as xenobiotics, 
that induce the synthesis of cytochrome P450, or (3) stimulation of a preexisting enzyme by a 
xenobiotic. By inducing cytochrome P450 one drug can stimulate the metabolism of a second 
drug and thereby decrease or increase its therapeutic effect. A dramatic effect of this type of drug 
interaction is the induction of ethinylestradiol metabolism by phenobarbital and rifampin, which 
can decrease the contraceptive effect of the former drug and lead to pregnancy. Allelic variants, 
which arise by point mutations in the wild-type gene, are another source of interindividual 
variation in P450 activity. Amino acid substitution can increase or, more commonly, decrease 
P450 enzyme activity, although the effect may be substrate-dependent. Examples of genetic 
factors that influence P450 activity are given below. The environmental factors which are known 
to affect P450 levels include medications (e.g. barbiturates, rifampin, isoniazid), food (e.g. 
cruciferous vegetables, charcoal-broiled beef), social habits (e.g. alcohol consumption, cigarette 
smoking), and disease status (diabetes, inflammation, hyperthyroidism and hypothyroidism). 
When environmental factors influence P450 enzyme levels, a considerable variation may be 
observed when xenobiotic biotransformation (e.g. drug metabolism) is measured repeatedly in 
the same individual. This variation is not observed when alterations in P450 activity are 
determined genetically. 
Cytochrome P450 enzymes play a dual role in the organism. On the one hand, they inactivate the 
drug/xenobiotic and prepare it for excretion. On the other hand, they are also capable of 
activating foreign chemicals to highly reactive toxic intermediates that might act as carcinogens 
or mutagens (Table 2). Hence, the accumulation of null alleles may convey some as yet 
unspecified advantage to heterozygous carriers (having only 1 defective allele). 
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Table 2: The role of enzymes of phases I and II in the biotransformation of drugs, toxic 
substrates and carcinogens. 
Toxic substrates, 
carcinogens 
Drugs Prodrugs Potential carcinogens 
↓ ↓ ↓ ↓ 
detoxification deactivation activation bioactivation 
Phase I of biotransformation 
↓ ↓ ↓ ↓ 
inactive metabolite active metabolite 
↓ ↓ ↓ ↓ 
loss appearance loss of toxicity/ 
carcinogenesis of pharmacodynamic effects 
appearance of toxicity/ 
carcinogenesis 
↓ ↓ ↓ ↓ 
Further detoxification during the phase II of biotransformation 
↓ ↓ ↓ ↓ 
Inactive water soluble or bile soluble metabolites 
 
 
1.1.1 Evolution of CYP450 genes 
P450s are found throughout the animal and plant kingdoms. If the phylogenetic tree is examined 
and correlated with catalytic activities of P450s, several suggestions can be made concerning 
P450 evolution. The earliest P450s are those that now metabolize steroids and fatty acids. The 
fatty acid-metabolizing P450IV family and the steroid-inducible P450III genes diverged more 
than 1 billion years ago. The P450I and P450II gene families formed about 800 million years ago 
and these genes are now responsible for the metabolism of drugs and carcinogens. Finally, about 
400 to 600 million years ago, the P450II gene family expanded into eight gene subfamilies. It 
has been suggested that this increase in the number of P450 genes was related to the emergence 
of mammals onto land several million years after plants had been established (Nels87). The 
presents of detoxifying enzymes allowed animals to survive in this hostile environment. 
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1.1.2 Cytochrome P450 1A1 (CYP1A1) 
A phenotypic polymorphism affecting CYP1A1 activity in humans was first described in 1973 
by Kellermann et al. (Kel73). The trimodal pattern of polycyclic aromatic hydrocarbons (PAHs) 
inducibility suggested that CYP1A1 was genetically regulated. Cytochrome CYP1A1 is a 
substrate-inducible microsomal enzyme that oxygenates PAHs generated from the combustion of 
fossil fuels, and aromatic amines, which are present in cigarette smoke, to carcinogens. In 
addition to cigarette smoke, inducers of the CYP1A1 enzyme include charcoal-broiled meat (a 
source of polycyclic aromatic hydrocarbons), cruciferous vegetables (a source of various indols), 
and omeprazole, a proton-pump inhibitor used to suppress gastric acid secretion. Reactions 
preferentially catalyzed by CYP1A1 include the hydroxylation and epoxidation of 
benzo[a]pyrene. 
Hildebrand et al. (Hil85) assigned the CYP1A1 gene to chromosome 15. Jaiswal and Nebert 
(Jai86) indicated that this locus is in the 15q22-qter segment. Several polymorphisms in the 
CYP1A1 gene have been described so far but they are relatively rare in Caucasians and their 
functional significance remains unclear. The first polymorphism discovered involves the 
transition of thymidine to cytosine at position 3801 of genomic DNA, conferring a restriction 
endonuclease site for cleavage by MspI (Spu87). This substitution occurs in the 3' noncoding 
region, downstream from exon 7 of the CYP1A1 structural gene. A second polymorphism, an 
A>G substitution at position 2455 in exon 7 of the CYP1A1 gene (Hay91a), results in an Ile to 
Val substitution at residue 462 near the heme binding region of the CYP1A1 protein. Another 
MspI polymorphism (m3), which has been described by Crofts et al. (Cro93) at nt 3205, was 
shown to be African black-specific. Mutation m4 (2453C>A), causing threonine to asparagine 
substitution, was described by Cascorbi et al. (Cas96c). The CYP1A1 promoter region contains 
at least three polymorphic sites (-4335G>A (Gai03)), -3229G>A, -3219C>T (Sma00)). These 
polymorphisms are located in the area of the gene which is well conserved between human and 
mouse (Jai85a). 
Mutations of CYP1A1 gene are presented in Figure 2. 
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m2 
2455A>G 
m3   
3205T > C   
m4 
2453C>A 
m5   
- 4335G > A   
m6 
- 3219C>T 
m7   
-3229G > A   
TATA box   
Retinoic acid responsive element  
Xenobiotic responsive elements  
EGF responsive elem ent   
T461N I462V 
m1 
3801T>C 
 
Figure 2: Polymorphisms in the human cytochrome P450 1A1. TATA box - the basal 
promoter contains a sequence of 7 bases (TATAAAA). EGF - epidermal growth factor. 
 
Table 3: Alleles of CYP1A1. 
m1 
3801T>C 
m2 
2455A>G 
m3 
3205T>C 
m4 
2453C>A 
m5 
-4335G>A 
m6 
-3219C>T 
m7 
-3229G>A Allele References 
T A T C G C G *1A (wt) 
Jai85a, Jai85b, 
Kaw86 
T A T C G T G *1B Sma00 
T A T C G C A *1C Sma00 
T A T C A C G *1D Gai03 
T A T C A C A *1E Gai03 
C A T C G C G *2A Spu87 
C G T C G C G *2B Hay91b 
T G T C G C G *2C 
Hay91b, Zha96, 
Pers97 
T A C C G C G *3 Cro93 
T A T A G C G *4 Cas96c 
 
In this study all known point mutations of the CYP1A1 gene were investigated and defined to 
alleles. 
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1.1.3 Cytochrome P450 2D6 (CYP2D6)   
It was shown in 1977 by Mahgoub et al. (Mah77) that a volunteer’s hypotensive response to 
debrisoquine, a sympatholytic antihypertensive drug, was markedly increased because of 
impaired metabolism. In 1975, Eichelbaum (Eic75) observed increased side effects which were 
associated with decreased oxidative metabolism of sparteine, an alkaloid drug with 
antiarrhythmic actions. Family studies revealed that these two oxidative metabolic reactions are 
under monogenic control and that poor metabolizers are homozygous for a recessive allele. 
Cytochrome P450 2D6 has been reported to catalyze the metabolism of about 25% of the 
clinically used drugs (Ben95), the most important of which are presented in Table 4. 
 
Table 4: Substrates of CYP2D6 (according to Bertz & Granneman (Ber97); Tucker 
(Tuc94); Brockmöller (Bro00); Caccia (Cac98)). 
Group of drugs  
Antiarrhythmic drugs Ajmalin, flecainide, mexiletine, propafenone, sparteine 
Tricyclic antidepressants Amitriptyline, clomipramine, nortriptyline, fluoxetine, desipramine, 
fluvoxamine 
Antihypertensives Debrisoquine, indoramine 
Beta-blockers Metoprolol, propranolol, timolol 
Neuroleptics Haloperidol, remoxipride, risperidone 
Opioide Codeine, dextromethorphan, galanthamine, tramadol 
Others Methylendioxymetamphetamine (“ecstasy”) 
 
 
The CYP2D wild-type locus in humans is comprised of the three highly homologous genes, 
CYP2D8P, CYP2D7P, and CYP2D6, which are located in this orientation (5' to 3') on a 
contiguous region of about 45 kb on chromosome 22q13.1 (Gon88, Kim89). CYP2D genes 
consist of nine exons and eight introns (Figure 3). CYP2D8P  and CYP2D8P were found to be 
pseudogenes. 
1   2   3 4  5 6 7 8  9
CYP2D8P CYP2D7P CYP2D6
1   2   3 4  5 6 7 8  9 1   2   3 4  5 6 7 8  9
CYP-REP-7 CYP-REP-6  
Figure. 3: Localization of CYP2D6 gene and of pseudogenes CYP2D7P and CYP2D8P in the 
CYP2D-geneclaster in chromosome 22. Repetitive elements are shown as grey boxes. 
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Seventeen different alleles of CYP2D6, associated with deficient, reduced, or increased activity, 
are known. They are termed according to the unified nomenclature developed by Daly et al. 
(Daly96a). Most alleles consist of point mutations, but a deletion of the entire gene (allele *5) and 
gene conversions, resulting in the «hybrid» alleles *13 and *16, also exist (Pan95, Daly96b). 
There are gene duplications of the*2  allele (*2x2; Joh93), as well as of the *1 and *4 alleles 
(Dah95, Lov96) and higher amplifications of the CYP2D6 genes (Joh93, Akl96). The most 
frequent inactivating mutation in Caucasians is the splice-site mutation 1934G>A defining the 
CYP2D6*4 allele (former type B allele), which results in a loss of enzyme activity. The alleles 
*2, *9, *10 and some others show slightly or moderately reduced activity in comparison with the 
wild-type allele *1. The poor metabolizer status is genetically based on the presence of a 
combination of any of a number of defective alleles. 
 
1.2 Phase II enzyme reaction 
Phase II enzymes are sometimes involved in metabolic activation, but usually conjugate various 
phase I products and other reactive intermediates, completing the detoxification cycle. With the 
exception of methylation and acetylation, phase II biotransformation reactions result in a large 
increase in the hydrophilicity of the xenobiotic, so they greatly promote the excretion of 
exogenous substances. Most phase II biotransforming enzymes are located in the cytosol; notable 
exceptions are the UDP-glucuronosyltransferases, which are microsomal enzymes. Phase II 
reactions generally proceed much faster than phase I reactions, such as those catalyzed by 
cytochrome P450. Therefore, the rate of elimination of xenobiotics, the excretion of which 
depends on the biotransformation by cytochrome P450 followed by phase II conjugation, is 
generally determined by the first reaction. Many phase II drug metabolizing enzymes have been 
shown to be polymorphically expressed, such as the N-acetyltransferases 1 and 2 (NAT1 and 
NAT2), the glutathione S-transferases M and T (GSTM and GSTT), and the thiopurine S-
methyltransferase (TPMT). 
 
1.2.1 Arylamine N-acetyltransferase 2 
N-acetylation is the major route of biotransformation for xenobiotics containing an aromatic 
amine (R-NH2) or a hydrazine group (R-NH-NH2), which are converted to aromatic amides (R-
NH-COCH3) and hydrazides (R-NH-NH-COCH3), respectively (Eva92). Like methylation, N-
acetylation masks the amine with a nonionizable group, so that many N-acetylated metabolites 
are less water soluble than the parent compounds. Nevertheless, N-acetylation of certain 
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xenobiotics such as isoniazid, facilitates their urinary excretion. In contrast to other xenobiotic-
biotransforming enzymes, the number of N-acetyltransferases is limited (Vat95).  
There exist two cytosolic N-acetyltransferases, namely NAT1 and NAT2. NAT1 is expressed in 
most tissues of the body, whereas NAT2 appears to be expressed only in the liver and the gut. 
NAT1 and NAT2 have different but overlapping substrate specificities, although no substrate is 
exclusively N-acetylated by one enzyme or the other. Substrates preferentially N-acetylated by 
NAT1 include para-aminosalicylic acid, para-aminobenzoic acid, sulfamethoxazole, and 
sulfanilamide, while substrates preferentially N-acetylated by NAT2 include isoniazid, 
hydralazine, procainamide, dapsone, aminoglutethimide, and sulfamethazine. Some xenobiotics, 
such as the carcinogenic aromatic amine, 2-aminofluorene, are acetylated equally well by NAT1 
and NAT2. 
The interindividual variation in NAT2 function is associated with the classical isoniazid 
acetylation polymorphism, which was discovered about fifty years ago by Bönicke and Reif 
(Bön53). As shown by the study of Evans et al. (Eva60), the «slow inactivator» person is 
homozygous for a slow inactivator allele, whereas the «rapid inactivator» is either homozygous 
or heterozygous for a rapid acetylator allele. Population studies show a distinct bimodal 
distribution of NAT2 phenotypes, as shown by Cascorbi et al. (Cas95), in 563 German subjects 
(Figure 4). 
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Figure 4: Histogram of NAT2 phenotypic activities as obtained by the caffeine test.  
Values represent the logarithmically transformed urinary metabolite ratio of 5-
acetylamino-6-formylamino-3-methyluracil/ 1-methylxanthin (AFMU/1X) after the intake 
of caffeine (Cas95). 
 
The association of the acetylation polymorphism with the risk of some kinds of malignant 
diseases (Eva92, Roo92) has received much attention. The slow acetylator phenotype was shown 
to be associated with a higher risk of bladder cancer (Car82, Ris95, Bro96), whereas the rapid 
acetylator phenotype is at a higher risk of developing colorectal cancer (Lan86, Pro95). 
NAT1 and NAT2 were mapped to chromosome 8p21.3-23.1 by Hickman et al. (Hic94). Each of 
the two genes NAT1 and NAT2 has a single, intronless protein-coding exon with an open reading 
frame of 870 bp. The nucleotide homology between NAT1 and NAT2 is 87% in the coding 
region. The pseudogene NATP has a high sequence homology to NAT1 and NAT2 but contains 
multiple frameshifts and stop codons and does not encode a protein (Blu90). Recent studies 
suggest that the NAT1 function may be genetically variable in human populations (Cri94, 
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Vat93). The NAT2 gene was first described by Blum et al. (Blu90). Since then eight different 
point mutations have been characterized (Vat91, LinH94, Bel93, Lef99). Among the eight point 
mutations in the coding region are five which cause amino acid changes: 191G>A (Arg to Glu), 
341T>C (Ile to Thr), 590G>A (Arg to Gln), 803A>G (Lys to Arg), 857G>A (Gly to Glu), and 
three silent ones: 111T>C, 282C>T and 481C>T (Figure 5). 
 
Mutation:           T/C    G/A   C/T  T/C    C/T    G/A               A/G  G/A
Position (nt):         | | | | | | | |
1    111     191     282   341          481         590         803   857      870
Amino acid     | | | | | | | |
changes: No Arg/Gln No  Ile/Thr No   Arg/Gln Lys/Arg  Gly/Glu  
Figure 5: Polymorphism in the human NAT2 gene. 
 
The point mutations of NAT2 form different alleles, which are presented in Table 5. Three 
nomenclatures of NAT2 alleles have been used so far. The M1 allele has mutations at positions 
341 and 481, M2 at positions 282 and 590, and M3 at position 857. According to the 
nomenclature of Vatsis et al. (Vat95), M1 corresponds to NAT2*5A, M2 to NAT2*6A, and M3 to 
NAT2*7A. Initially, only one mutation was reported at position 857 for NAT2*7A. Vatsis et al. 
(Vat95) described an allele, containing mutations at positions 341, 481 and 803 (NAT2*5B). 
Hickman et al. (Hic92) observed an allele with mutations at positions 341 and 803 (NAT2*5C). 
Moreover, Bell et al. (Bel93) described a mutation at position 191 that occurs almost exclusively 
in Blacks. The novel NAT2*6D allele was described by Leff et al. (Lef99). 
 
Table 5: Alleles of NAT2. 
Nucleotide positions of point mutations 
NAT2-allele 
111 191 282 341 481 590 803 857 
NAT2*4 T G C T C G A G 
NAT2*5A T G C C T G A G 
NAT2*5B T G C C T G G G 
NAT2*5C T G C C C G G G 
NAT2*6A T G T T C A A G 
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NAT2*6D C G T T C A A G 
NAT2*7B T G T T C G A A 
NAT2*12A T G C T C G G G 
NAT2*14A T A C T C G A G 
NAT2*14B T A T T C G A G 
 
The wild-type NAT2*4 (Blu90) allele and the rare NAT2*12A (Cas96a) allele are associated with 
the rapid acetylator phenotype. Eight alleles of the NAT2 gene are coding for the slow 
phenotype. The In-vivo acetylation capacity is significantly higher in homozygous wild-type 
subjects than in heterozygous genotypes. 
 
1.3 The purpose of the work 
 
1. The purpose of this work was the investigation of the frequency of functionally 
important mutations, alleles and genotypes of the polymorphic cytochromes P450 1A1 
and 2D6 and arylamine N-acetyltransferase 2 in a group of 325 healthy Russian 
volunteers and the comparison of our data with corresponding frequencies of other 
ethnic groups. 
2. In addition, a real time PCR method, which combines a microvolume fluorimeter with a 
rapid temperature cycler, was optimized for the detection of the NAT2 polymorphism. 
This method is easy, reliable and fast, and allows to genotype hundreds of samples in 
one day. 
3. The results of the study should provide the basis of a pharmacogenetic databank for the 
Russian population, which is the biggest Slavic group. 
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2 Materials and methods 
2.1 Patients 
We have investigated 325 (174 males, 151 females) unrelated individuals from the European part 
of Russia (Voronezh and region). The mean age (±SD) was 40.9±16.4 years (range 14-77). 
Except for 76 healthy volunteers, subjects were outpatients with non-malignant diseases 
recruited from the departments of  otorhinolaryngology (158), surgery (47), neurology (41) and 
traumatology (3) (Table 6) at the Central Railway Clinic in Voronezh. All subjects were 
informed about the contents and aims of the study and gave their written consent. When the 
participants were under 18 years old, the written consent was given by their parents. Information 
about present or former smoking habits was collected from all the participants. The study was 
approved by the Central Moscow Ethics Committee.  
 
Table 6: Characteristics of study participants. 
Percentiles
Participants n 
Age range 
(years) 
Mean age 
(years) 
Median age 
(years) 25 75 
Total 325 14-77 41.6 ± 16.4 41.0 25.0 54.0
Males 174 15-73 38.7 ± 16.2 38.0 23.0 51.3
Females 151 14-77 43.3 ± 16.2 45.0 29.0 57.0
Healthy volunteers 76 18-61 27.4 ± 10.9 23.0 21.0 28.3
Dept. of  otorhinolaryngology 158 14-74 43.0 ± 15.8 43.0 31.0 54.8
Dept. of surgery 47 16-77 50.2 ± 15.2 52.0 37.0 62.0
Dept. of neurology 41 21-67 47.6 ± 12.9 49.0 42.0 57.0
Dept. of traumatology 3 44-72 55.0 ± 14.9 49.0 44.0 72.0
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2.2 Materials 
2.2.1 Chemicals 
The following chemicals and solutions were used for DNA extraction and molecular genetic 
investigations. 
Table 7: Chemicals used for investigation.  
Chemicals Manufacturer 
DNA polymerase AmpliTaq™, 
10x PCR buffer, 25 mM MgCl2 
Perkin Elmer 
DNTPs Boehringer Mannheim 
Restriction endonucleases 
KpnI, BamHI, TaqI, MspI, FokI, DdeI,  
BstNI, BanII, HphI, 
BsrDI, BsaI, HhaI, BslI, NcoI 
New England Biolabs 
DNA oligonucleotides (PCR primers) TIB-Molbiol 
Hybridization probes TIB-Molbiol 
100 bp and 1 kb DNA marker MBI Fermentas 
marker V and marker VI Boehringer Mannheim 
Proteinase K Boehringer Mannheim 
Agarose ultrapure, agarose NuSieve  Gibco BRL, Biozym  
Expand™ Long PCR System Boehringer Mannheim 
 
Table 8: Solutions used for DNA extraction and gel preparation. 
Solution Contents 
Lysis buffer NH4Cl (155 mM), KHCO3 (10 mM),  EDTA  (0.1 mM); pH 8.0 
TEN-buffer Tris/HCl (20 mM), EDTA (2mM), NaCl (30 mM); pH 7.5 
20% SDS 2 mg sodium dodecylsulfate (Merck) in 100 ml H2O 
Phenol solution Phenol/chloroform/water (Perkin Elmer) 
Chloroform solution Chloroform, isoamylic alcohol (49:1)  
Sodium acetate 40.8 g CH3COONa (3 M) fill up ad 100 ml H2O; pH 5.5 
TE buffer Tris-HCl (10 mM), EDTA (1mM) fill up ad 100 ml H2O; pH 8.0 
TBE buffer Tris (90 mmol/l), boric acid (90 mmol/l), EDTA (2.5 mmol/l); pH 8.0-
8.3 
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2.2.2 Equipment 
The experimental part of the work was done in the Institute of Clinical Pharmacology, Charité, 
Berlin. The equipment used is listed in Table 9. 
 
Table 9: Instruments used for experiment. 
Instruments Manufacturer 
Thermocyclers: Gene Amp PCR System 9600 
and 9700 
Perkin Elmer/Applied Biosystems 
LightCycler Roche Diagnostics Inc. 
Video detection system Eagle Eye Stratagene 
Incubation ovens Biometra 
Centrifuges Eppendorf, Beckman, Sigma 
Several semi-automatic shakers Hoefer, Heidolf, Janke & Kunkel 
Electrophoresis chambers and 
Electrophoresis power supplies 
Pharmacia, Biorad, Hoefer 
 
 
2.3 Methods 
2.3.1 DNA extraction 
DNA was extracted manually by the phenol-chloroform method, according to Sambrook et al. 
(Sam89). Ten ml of blood were taken from each patient and mixed with a solution of ethylene 
diamine tetraacetic acid (1.6 mg EDTA/ml of blood). Then 40 ml of 1x lysis buffer were added 
and the sample was incubated in ice for 30 min. Samples were centrifuged at 2000 rpm at 4°C 
for 30 min. The supernatant liquid was removed, the cell pellet was dissolved in 1.5 ml 1x TEN 
buffer and stored at -20°C. For the genotyping procedure, the samples were transported in dry ice 
to Berlin. After thawing the cell suspension was mixed with 100 µl 20% SDS solution and 100 
µl proteinase K solution and, being shaken at 40 1/min, incubated at 37°C overnight. Next day 
1.5 ml of phenol were added to the proteinase-digested cell suspension which was then shaken 
for 3 hours in an overhead-shaker at 30 1/min. Then tubes were centrifuged at 3000 rpm for 5 
min to separate phases. The upper, DNA containing phase, was transferred into a 12-ml reaction 
tube. In the next extraction step lipids were removed from the DNA solution by adding 1.5 ml 
chloroform solution and shaking in an overhead shaker (30 1/min) for 1 hour. Phases were 
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separated by centrifugation at 3000 rpm for 5 min. The DNA containing upper phase was 
carefully transferred into fresh 12-ml tubes. DNA was precipitated by adding 100 µl of 3 M 
sodium acetate (pH 5.5) and 6 ml of 96% ethanol, tubes were mixed well and centrifuged (10 
min 3000 rpm). All supernatant liquid was removed. Three ml of 70% ethanol were added to the 
DNA, mixed well and centrifuged (10 min 3000 rpm). The supernatant liquid was removed and 
DNA was dried by placing the tubes overhead on filter paper for 10 min. Dried DNA was 
dissolved in 600 µl TE buffer and incubated at 55°C overnight, simultaneously slightly agitated 
at 40 1/min. On the next day the DNA solution was transferred into labelled 1.5-ml sterile 
Eppendorf reaction tubes and samples were stored at 4°C. DNA concentrations were measured 
with a spectrophotometer (Eppendorf, Germany) and, when necessary, DNA was diluted to the 
concentration of 30 ng/µl. 
 
2.3.2 Genotyping methods 
2.3.2.1 Polymerase chain reaction/ restriction fragment length polymorphism (PCR-
RFLP) 
The investigation of genes encoding drug metabolizing enzymes was performed using 
polymerase chain reaction (PCR). The main principle of PCR is the exponential amplification of 
the part of DNA which contains the gene of interest. The amplification product can be analyzed 
for genomic alterations (mutations, deletions, translocations). For successful PCR, about 50-60 
ng DNA, DNA-polymerase, deoxyribonucleotide triphosphates (dATP, dCTC, dGTP and dTTP) 
and two specific primers should be incubated under specific conditions. The PCR procedure 
includes three consecutive phases. During the first phase the DNA is denatured by heating to 
95°C. In the next phase (annealing, 55-65°C), primers hybridize to the complementary parts of 
single-strand DNA-matrix. During the third part of PCR (extension, 72°C), the formation of the 
second strand is completed. In the following cycles, the newly formed molecules of DNA are 
used as matrix. The number of cycles in one PCR is 25-35, these are necessary to obtain enough 
genetic material for further analysis. Five µl of PCR-product are analyzed in a 1% agarose gel. 
Positive samples can be used for further investigations. The PCR-product is digested using 
restriction endonucleases, which results in fragments the lengths of which depend on the 
genotype. Heterozygous individuals have fragments typical for both wild-type and mutant 
alleles. The digest is mixed with 10 µl of blue buffer (Life Technologies) and fragments are 
separated in the 2-4% gel. 4.5µl of DNA-marker are used as a size standard of fragments. 
Results are documented using the video detection system Eagle Eye. 
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2.3.2.2 LightCycler assay 
The  hybridization probe format is used for DNA detection and quantification and provides 
maximum specificity for product identification. In addition to the reaction components used for 
conventional PCR, two specially designed, sequence-specific oligonucleotides labelled with two 
different fluorescent dyes are utilised for this detection method. The detection is based on the 
generation of a fluorescent signal by fluorescence resonance energy transfer (FRET), which is 
released when two probes bind to the target sequence. 
 
Fluorophore 
donor
Fluorophore 
acceptor
DNA Target
Fluorescence 
signal
Donor excitation by an external light 
source leads to the emission of 
fluorescence by energy transfer
 
Figure 6: PCR monitoring with hybridization probes. 
 
The LightCycler method allows highly specific detection of the amplification product as 
described below. Figure 6 shows the three essential components for using fluorescence-labelled 
oligonucleotides as hybridization probes: two differently labelled oligonucleotides and the 
amplification product. Oligo 1 carries a fluorescein label at its 3' end whereas oligo 2 carries 
different label (LC Red 640 or LC RED 705) at its 5' end. The sequences of these two 
oligonucleotides are selected in such a way that they hybridize to the amplified DNA fragment in 
a head to tail arrangement. When the oligonucleotides hybridize in this orientation, the two 
fluorescence dyes are positioned in close proximity to each other. The first dye (fluorescein) is 
excited by the LightCycler's LED (Light Emitting Diode) filtered light source, and emits green 
fluorescent light at a slightly longer wavelength. When the two dyes are in close proximity, the 
emitted energy excites the LC Red 640 attached to the second hybridization probe that 
subsequently emits red fluorescent light at an even longer wavelength. This energy transfer, 
 28
referred to as FRET, is highly dependent on the spacing between the two dye molecules. Only if 
the distance between the two molecules does not exceed 5 nucleotides is the energy transferred 
very efficiently. When the appropriate detection channel is chosen, the intensity of the light 
emitted by the LightCycler – Red 640 is filtered and measured by the LightCycler's optics. The 
increasing amount of measured fluorescence is proportional to the increasing amount of DNA 
generated during the ongoing PCR process. Since LC Red 640 only emits a signal when both 
oligonucleotides are hybridized, the measurement of fluorescence is performed after the 
annealing step. 
 
 
2.3.2.3 Genotyping of CYP1A1 mutations 
Seven polymorphic sites of the polymorphic CYP1A1 were analyzed. 
PCR No. 1 Amplification of a 899-bp fragment (detection of mutations m1 and m3). 
An 899-bp fragment, containing polymorphic sites m1 and m3, was amplified with the forward 
primer M3F and the reverse primer P80 (Table 10). PCR reactions included 2.5 µl PCR-buffer, 
2.5 µl 2 mmol/l dNTPs, 0.5 µl of each of the primers, 0.5 U Taq-DNA-polymerase, 2.4 µl 25 
mmol/l MgCl2 and 50 ng of genomic DNA in a total volume of 25 µl. Amplification was 
performed with an initial denaturation at 94°C for 2 min, 35 cycles with at 94°C for 30 s, at 63°C 
for 30 s, at 72°C for 1 min, and a final elongation at 72°C for 7 min. 
The PCR-product, containing an 899-bp fragment, was digested with restriction enzyme MspI at  
37°C overnight. 
M     1      2      3      M
898 bp
692 bp
206 bp
1: 3801CC; 693, 206 bp
2: 3801TC; 899,  693, 206 bp
3: 3801TT; 899 bp
 
Abb. 7: MspI digest of an 899-bp fragment containing the positions of the m1/m3 
mutations. 
Fragments were colored with 1mg/l Ethidium Bromide. 
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PCR No. 2. Amplification of a 204-bp fragment (detection of mutations m2 and m4). 
For the detection of the m2 and m4 mutations, a 204-bp fragment was amplified with the primers 
M2F and M2R. A 50-µl PCR mix contained 5 µl PCR- buffer, 5 µl 2 mmol/l dNTPs, 4.8 µl 25 
mmol/l MgCl2, 1 µl of each of the primers, 1 U Taq-polymerase, 35.4 µl H2O and 50 ng of 
genomic DNA. Thermocycling conditions were the same as for the PCR No.1. BsrDI and BsaI  
were used as restriction enzymes for m2-digestion and for m4-digestion, respectively. The 
restriction-fragment lengths are given in Table 11. The digestion products were analyzed on a 
3% agarose gel, together with a 100-bp DNA weight marker. 
 
M   1   2      3    M
204 bp
149 bp
55 bp
1: 2455GG; 204 bp
2: 2455AG; 204, 149, 55 bp
3: 2455AA; 149, 55 bp
 
Figure 8: BsrDI digest of a 204-bp fragment containing the positions of the m2 mutation. 
 
 
M      1      2      3      M
204 bp
139 bp
65 bp
1: 2453CC; 139, 65 bp
2: 2453CA; 204, 139, 65 bp
3: 2453AA; 204 bp
 
Figure 9: BsaI digest of a 204-bp fragment containing the positions of the m4 mutation. 
 
 
PCR No. 3 Amplification of a 157 bp-fragment (detection of the new polymorphism m5). 
PCR with the primers Hha-F and Hha-R resulted in the amplification of a 157-bp fragment. The 
mastermix contained 2.5 µl PCR-buffer, 2.5 µl 2 mmol/l dNTPs, 1 µl of each of the primers, 0.5 
U Taq-polymerase, 2 µl 25 mmol/l MgCl2, 15.9 µl H2O, and 50 ng of genomic DNA. PCR-
conditions were as follows: an initial denaturation at 94°C for 2 min, 35 cycles at 94°C for 20 s, 
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at 55°C for 10 s, at 72°C for 40 s and at 72°C for 7 min. The PCR-product was digested with 
HhaI at 37°C for 2 hours. 
 
PCR No.4 Amplification of a 284-bp fragment (detection of the mutations m6 and m7). 
For the detection of possible m6 and m7 mutations, a PCR-amplified 284-bp fragment was used. 
A 50-µl PCR mix contained 5 µl PCR-buffer, 5 µl 2 mmol/l dNTPs, 1 µl of each of the primers 
1A1-M5F and 1A1-M5R, 1 U Taq-polymerase, 4 µl 25 mmol/l MgCl2, 33.8 µl H2O and 50 ng of 
genomic DNA. The amplification was performed with an initial denaturation at 94°C for 2 min, 
35 cycles at 95°C for 30 s, at 60°C for 1 min, at 72°C for 30 s, and a final elongation at 72°C for 
7 min. The PCR-product, containing a 284-bp fragment, was subject to digestion with enzymes 
BslI and NcoI for the detection of m6 and m7 mutations. 
 
M       1        2         M
149 bp
106 bp
88 bp
1: -3219CC; 106, 88, 43, 24, 23 bp
2: -3219CT; 149, 106, 88, 43, 24, 23 bp
 
Abb. 10: BslI digest of a 284-bp fragment containing the positions of the m6 mutation. 
 
Table 10: Primers for CYP1A1 genotyping. 
Fragment Primer 
length (bp) 
Sequence 
M3F 899 5'-GGCTGAGCAATCTGACCCTA 
P80 - 5'-TAGGAGTCTTGTCTCATGCCT 
M2F 204 5'-CTGTCTCCCTCTGGTTACAGGAAGC 
M2R - 5'-TCCCACCCGTTGCAGCAGGATAGCC 
Hha-F 157 5'-TGGGGCATATTACTTGTCTCCTT 
Hha-R - 5'-CGGCCTCGTGCATTGCAGAAATA 
1A1-M5F 284 5'-GAACCTCAGCTAGTCGCCC 
1A1-M5R - 5'-AGAGAGGGTACGGGAAGCTC 
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Table 11: Restriction endonucleases for recognition of CYP1A1 mutations. 
Mutation Position Transition 
Restriction 
endonuclease 
Recognition 
sequence 
Preamplifica-
tion with 
primers 
Fragment-length (bp) 
Wild type*  
Mutation 
899 
m1 3801 T>C MspI C^CGG M3F/P80 
693   206 
149  55 
m2 2455 A>G BsrDI 
GCAATGnn
^ 
M2F/M2R 
204 
899 
m3 3205 T>C MspI C^CGG M3F/P80 
802   97 
139   65 
m4 2453 C>A BsaI 
GGTCTCn^
nnnn 
M2F/M2R 
204 
94   63 
m5 -4335 G>A HhaI GCG^C 
HhaI-F/ HhaI-
R 157 
106 88 43 24 23 
m6 -3219 C>T BslI 
CCnnnnn^n
nGG 
1A1-5F/ 1A1-
5R 149 88 24 23 
284 
m7 -3229 G>A NcoI C^CATGG 
1A1-5F/ 1A1-
5R 141   143 
 
*First line, wild-type fragment; second line, mutant fragment 
 
 
2.3.2.4 Genotyping of CYP2D6 mutations 
For the detection of the most functionally important alleles *1,*3,*4,*5,*6,*10  and the gene 
duplication of CYP2D6, combined PCR-RFLP tests were used, as described by Sachse et al. 
(Sac97). The first step was the amplification of a 4681-bp genomic DNA fragment, which 
contained all nine CYP2D6 exons, using the Expand Long Template PCR SystemTM. Figure 11 
shows consecutive steps of CYP2D6 genotyping. 
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9
Exon: 1  2   3 4   5 6  7  8 9
CYP2D8 CYP2D7 CYP2D6
1 4681 bp
Exon:
CYP2D8 CYP2D7
CYP2D6
Exon:                 1      2        3       4        5   6     7        8    9
5 3500 bp
Detection of CYP2D6*5 deletion 
Detection of CYP2D6*MxN duplication 
Exon:
CYP2D7 CYP2D6 -dup CYP2D6
2 433 bp 3 353 bp 4 201 bp
7 10000 bp
6 3600 bp
264 bp 8 433 bp
1  2   3 4   5 6  7  8 91  2   3 4   5 6  7  8 9
1  2   3 4   5 6  7  8 9 1  2   3 4   5 6  7  8 9
1  2   3 4   5 6  7  8 9 1  2   3 4   5 6  7  8 91  2   3 4   5 6  7  8 9
 
Figure 11: Design of the PCR tests for CYP2D6 mutations. 
The bold numbers indicate the RCP reactions which are described in the text. 
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Table 12: PCR-RFLP tests for CYP2D6 genotyping. 
PCR-RFLP assay  RFLP-fragment patterns [bp] 
PCR
No. 
Detected 
mutation PCR primers 
Fragment 
length 
[bp] 
Restriction
enzyme 
 
Wild-type 
allele 
Mutant allele 
1 entire CYP2D6 P100/P200 4681 -  4681 
no fragment in 
cases of *5/*5 
2 188C>T P113/P121 433 HphI  362/71 262/100/71 
3 
1795T>Del 
1934G>A 
P*3/P2 353 
BstNI 
BstNI 
 
190/163 
190/163 
190/139/123 
353 
4 2637A>Del P51/D2 201 BsaAI  201 180/20 
5 *5 P13/P24/P81 3500 -  4500 3500 
6 CYP2D6*MxN P17/P32 3600 -  5200 5200/3600 
7 CYP2D6*MxN P2x2f/P2x2r 10000 -  no fragment 10000 
8 CYP2D6*4xN P113/P121 433 HphI  *1, *2: 362/71 *4: 262/100/71
9 CYP2D6*1xN P2x2f/P92 264 BanII  *1: 231/33 *2, *4: 264 
 
 
PCR No.1 Amplification of the entire CYP2D6 gene. 
The amplification of the whole CYP2D6 gene (4681-bp fragment) was performed according to 
Sachse et al. (Sac97). A 25-µl PCR mix contained 2.5 µl PCR-buffer, 4.5 µl 2 mmol/l dNTPs, 0.5 
µl of each of the primers P100 and P200 (all primers are given in Table 13), 1.25 U Taq-
polymerase, 16.75 µl of H2O, and 80-100 ng of genomic DNA. Thermocycling conditions were 
as follows: initial denaturation at 94°C for 2 min, 35 cycles of denaturation at 96°C for 10 s, 
annealing at 57°C for 20 s, and extension at 68°C for 5 min. The terminal elongation was 
performed at 68°C for 7 min. If the PCR was successful (checked by 1% agarose gel 
electrophoresis), 15 µl of the PCR product were diluted with 5 volumes of distilled water and 
stored at 4°C. 
 
PCR No. 2 Detection of the mutation 188C>T (alleles *4 and *10). 
Nested PCR was performed using the PCR product of reaction No. 1. A 433-bp fragment was  
amplified at 94°C for 2 min, 25 cycles at 95°C for 30 s, at 58°C for 10 s, at 72°C for 1 min, and 
terminal extension at 72°C for 7 min. A 25-µl PCR mix contained 2.5 µl PCR-buffer, 2.5 µl 2 
mmol/l dNTPs, 1.25  µl  25 mmol/l   MgCl2, 0.5 µl of each of the primers P113 and P121, 1.25 
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U Taq-polymerase, 17.5 µl H2O, and 1 µl of the diluted 4681 PCR-product. The PCR-product 
was digested with enzyme HphI at 37°C overnight. 
 
M     1      2       3      M
362 bp
262 bp
100 bp
1: 188TT; 262, 100, 71 bp
2: 188CT; 362, 262, 100, 71 bp
3: 188CC; 362, 71 bp.
 
Figure 12: HphI digest of a 433-bp fragment containing position 188 of the CYP2D6 gene.  
 
 
PCR No. 3 Detection of mutations 1795 T>Del and 1934G>A (alleles *4 and *6). 
PCR No. 4 Detection of mutations 2637A>Del (allele *3). 
In the subsequent nested PCRs, conditions were as follows: initial denaturation at 94°C for 2 
min, 25 cycles at 95°C for 10 s, at 60°C for 10 s, at 72°C for 1 min, and terminal extension at 
72°C for 7 min. A 25-µl PCR mix contained 2.5 µl PCR- buffer, 2.5 µl 2 mmol/l dNTPs, 1.25  µl  
25 mmol/l   MgCl2, 0.5 µl of each of the primers, 1.25 U Taq-polymerase, 17.5 µl H2O and 1 µl 
of the diluted 4681 PCR-product. After amplification, the products of nested PCRs were 
analyzed by an 1% agarose gel electrophoresis and digested with the respective restriction 
endonucleases. The enzymes and restriction-fragment lengths are given in Table 12. The 
digestion products were analyzed on a 3% agarose gel, together with a 100-bp DNA weight 
marker. 
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353 bp
190 bp
163 bp
139 bp
1: 1795TT, 1934GG; 190, 163 bp
2: 1795TT, 1934GA; 353, 190, 163 bp
3: 1795TT, 1934AA; 353 bp
4: 1795TDel, 1934GG; 190, 163, 139, 23 bp
1         M         2          3          4
 
Figure 13: BstNI digest of a 353-bp fragment containing the mutations 1795T>Del and 
1934G>A of the CYP2D6 gene. 
 
201 bp
180 bp
1: 2637A/*3; 201, 180, 20 bp
2: 2637AA; 201 bp
1       2       M
 
Figure 14: BsaAI digests of a 201-bp fragment for the detection of the mutation 
2637A>Del. 
 
 
PCR No. 5 Detection of CYP2D6 deletion (allele *5). 
 
1: allele *5 positive, 3500 bp
2: allele *5 negative, 4500 bp
4500 bp
3500 bp
1 2            M
 
Figure 15: Electrophoresis of the PCR-product from reaction No. 5 for detection of the 
CYP2D6 deletion. 
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PCR No. 6 Detection of CYP2D6 duplication (allele *MxN). 
For the detection of the CYP2D6 deletion (allele *5) and duplication (*MxN), PCR methods were 
established from literature. The CYP2D6 deletion detecting assay (Ste95) was improved, 
according to Sachse et al. (Sac97), by adding an internal standard primer. This primer enables 
genotype independent amplification of an internal standard fragment, as in the CYP2D6 
duplication assay of Løvlie et al. (Lov96). These internal standard fragments ensure that false 
negative results are not possible in these two assays. In both PCRs, a standard fragment, and – if 
the deletion or duplication allele occurs – a second fragment are amplified from genomic DNA. 
After having transferred the product of the enzymatic digestion in 1% agarose gel, it was 
submitted to electrophoresis, and the results were documented by a digital video system. Long 
distance PCR technique was applied using the same concentrations of PCR compounds and PCR 
conditions as described above for the PCR reaction amplifying the entire CYP2D6. 
 
1            2           M
5200 bp
3600 bp 1: duplication *MxN-negative; 5200 bp
2: duplication *MxN-positive; 5200, 3600 bp
 
Figure 16: Electrophoresis of the PCR-product from reaction No. 6 for detection of the 
CYP2D6 duplication. 
 
 
PCR No. 7 Detection of CYP2D6 duplication (allele *MxN). 
In 3 cases of allele duplication and genotype *1/*4, PCR No. 7 was established according to 
Johansson et al., 1996 for the detection of duplicated allele. The PCR conditions were as 
follows: an initial denaturation at 94°C for 2 min, 10 cycles at 96°C for 10 s, at 57°C for 20 s, at 
68°C for 12 min, 20 cycles at 96°C for 10 s, at 57°C for 20 s, at 68°C for 12 min + 15 s per cycle 
and terminal extension at 68°C for 7 min. A 25-µl PCR mix contained 2.5 µl PCR-buffer, 6.25 
µl 2 mmol/l dNTPs, 0.75 µl of each of the primers P2x2f and P2xr, 1.85 µl of enzyme mix (Taq 
and Pwo polymerases), 11.5 µl H2O and 80-100 ng of genomic DNA. The PCR resulted in a 
10000-bp fragment, which is a fragment between exon 9 of allele 1 and intron 2 of allele 2. 
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PCR No. 8 Detection of CYP2D6 duplication (allele *4xN). 
PCR No. 9 Detection of CYP2D6 duplication (allele *1xN). 
To distinguish between different types of allele duplication, two additional PCR-RFLP tests were 
developed, both as nested PCR from the diluted product of reaction 7. A PCR-RFLP test 
detecting the *2-related 4268G>C mutation (reaction 8) showed whether *1 or *2 was duplicated 
(in *1x2/*2 or *2x2/*1 constellation). The primers P2x2f and P92 were used to amplify a 264-bp 
product (PCR conditions as for reaction 3), which was digested using BanII. 
Performing reaction 9 (same conditions as in reactions 3 and 8) using the 10-kb gene duplication 
product as a target, the detection of the *4-associated 188C>T mutation by HphI digestion served 
as an indirect proof of a duplicated *4 allele in cases of a questionable *2x2/*4 or *4x2/*2 
constellation. 
 
Table 13: Sequences and locations of primers used in PCR reactions. 
Primer Sequence Orientation and position* Specificity 
P100 5'-GGCCTACCCTGGGTAAGGGCCTGGAGCAGGA f -180 -150 
P200 5'-CTCAGCCTCAACGTACCCCTGTCTCAAATGCG r +92 +123 
whole CYP2D6 
gene 
P*3 5'-CCTGGGCAAGAAGTCGCTGGACCAG f 1770 1794 
P2 5'-GAGACTCCTCGGTCTCTCG r 2104 2122 
alleles *4 and *6 
P51 5'-GCTGGGGCCTGAGACTT f 2457 2473 
D2 5'-GGCTGGGTCCCAGGTCATAC r 2638 2657 
allele *3 
P13 5'-ACCGGGCACCTGTACTCCTCA f (2D7) +1619 +1639  
P24 5'-GCATGAGCTAAGGCACCCAGAC r +3444 +3465 
P81 5'-CGTCTAGTGGGGAGACAAAC f 3621 3640 
allele *5 
P17 5'-TCCCCCACTGACCCAACTCT f (2D7) +155 +174 
P32 5'-CACGTGCAGGGCACCTAGAT r (2D7) +5470 +5489  
P2x2f 5'-GCCACCATGGTGTCTTTGCTTTC f 4238 4260 
P2x2r 5'-ACCGGATTCCAGCTGGGAAATG r 1384 1405 
CYP2D6 
duplication  (allele 
*MxN) 
P113 5'-TCAACACAGCAGGTTCA f -82 -66 
P121 5'-CTGTGGTTTCACCCACC r 335 351 
alleles *10, *4xN 
P92 5'-CTCAGCCTCAACGTACCCCT r +104 +123 allele *1x2 
Underlined nucleotides refer to mismatched bases 
*Position according to Kimura et al. (Kim89) 
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2.3.2.5 Genotyping of NAT2 mutations 
Eight polymorphic sites of NAT2 were analyzed.  
PCR No. 1 Amplification of the whole exon of the NAT2 gene (detection of the mutations 
481C>T and 857G>A). 
The whole exon (1211-bp fragments) of the NAT2 gene was amplified. 50-80 ng of target DNA 
was amplified in a 50-µl reaction mix, which contained 5 µl PCR-buffer, 5 µl 2 mmol/l dNTPs, 1 
µl of each of the primers P100 and P56, 1 U Taq-polymerase, 4.8 µl 25 mmol/l MgCl2, and 33.2 
µl H2O. Thermocycling conditions were as follows: initial denaturation at 94°C for 2 min; 35 
cycles of denaturation at 94°C for 30 s, annealing and elongation at 67°C for 90 s, and terminal 
extension at 72°C for 7 min. The PCR result was checked by electrophoresis in 1% agarose gel.  
From the PCR-product which contained the 1211-bp fragment, two restriction digests were 
performed with the enzymes KpnI and BamHI for the detection of mutations 481C>T and 
857G>A. The remaining PCR-product was diluted 1:10 by adding 162 µl H2O until a final 
volume of 180 µl was reached. 
 
M   1 2       3 M
1211 bp
662 bp
549 bp
1: 481CT; 1211, 662, 549 bp
2: 481TT; 1211 bp
3: 481CC; 662, 549 bp
 
Figure 17: KpnI digest of a 1211-bp fragment, containing positions for mutation 481C>T. 
 
M 1    2       3   M
1211 bp
925 bp
286 bp
1: 857AA; 1211 bp
2: 857GG; 925, 286 bp
3: 857GA; 1211, 925, 286 bp
 
Figure 18: BamHI digest of a 1211-bp fragment, containing positions for mutation 
857A>G. 
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PCR No. 2 Detection of mutations 191G>A, 282C>T, 341T>C and 111T>C. 
The nested PCR, using the primers P100 and P341N, was performed for the amplification of a 
442-bp fragment, which contains the mutations 191G>A, 282C>T, 341T>C and the novel 
mutation 111T>C. One µl of the diluted PCR-product (P100/P56) was added to the mastermix. 
PCR-conditions were as follows: an initial denaturation at 94°C for 2 min, 14 cycles at 94°C for 
0.5 min, at 67°C for 1.5 min and terminal elongation at 72°C for 7 min. For evaluation at nt 
position 111, 12.5 µl of PCR-product (P100/P341N) were incubated with the restriction 
endonuclease TaqI (10 U) at 65°C for 3-4 hours. Further mutations at positions 191 and 341 
were investigated by overnight digestion of a 442-bp fragment with the endonucleases MspI (50 
U) and DdeI (5 U) at 37°C. For evaluation at nt position 282, the PCR-product was digested with 
FokI (15 U) enzyme at 37°C for 2 hours.  
The restriction-fragment lengths are presented in Table 15. 
 
M     1       2      3      M
442 bp
337 bp
105 bp
1: 282CC; 337, 105 bp
2: 282CT; 442, 337, 105 bp
3: 282TT; 442 bp
 
Figure 19: FokI digest of a 442-bp fragment containing positions of the mutation 282C>T. 
 
M      1      2      3       M
220 bp
188 bp
163 bp
1: 341TT; 220, 163, 59 bp
2: 341TC; 220, 188, 163, 59, 32 bp
3: 341CC; 188, 163, 59, 32 bp
 
Figure 20: DdeI digest of a 442-bp fragment containing positions of the mutation 341T>C 
 
PCR No. 3 Detection of mutations 590G>A and 803A>G. 
For the detection of mutations at the positions 590 nt and 803 nt nested PCR with the primers 
P87 and P90 was performed from the initial 1211-bp amplificate (an initial denaturation at 94°C 
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for 2 min; 14 cycles at 94°C for 0.5 min, at 60°C for 1 min, at 72°C for 1 min; at 72°C for 7 min) 
and resulted in a 421-bp fragment. 1 µl of the PCR-product (P100/P56), which had been diluted 
1:10, was added to the mastermix. 12.5 µl of the PCR-product were incubated with 10 TaqI U at 
65°C for 3-4 hours for the detection of the mutation at position 590. Overnight digestion of 12.5 
µl of the PCR-product was performed with 5 U DdeI at 37°C to detect the mutation at position 
803. 
 
279 bp
170 bp
142 bp
109 bp
1: 590GA; 279, 170, 142, 109 bp
2: 590AA; 279, 142 bp
3: 590GG; 170, 142, 109 bp
M      1      2      3      M
 
Figure 21: TaqI digest of a 421-bp fragment containing positions of the mutation 590G>A. 
 
 
M      1  2       3     M 
297 bp
124 bp
97 bp
1: 803AG; 297, 124, 97, 27 bp
2: 803AA; 297, 124 bp
3: 803GG; 297, 97, 27 bp
 
Figure 22: DdeI digest of a 421-bp fragment containing positions of the mutation 803A>G. 
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Table 14: Oligonucleotide-primers for amplification of coding regions of the NAT2-gene 
and amplification of small fragments containing possible mutations at positions 111, 191, 
282, 341, 481, 590, 803 and 857. 
Primer Primer- 
length (nt) 
Fragment-
length (bp) 
Sequence Specificity 
P100 -69- -48 1211 5'-GTCACACGAGGAAATCAAATGC NAT2-gene (5') 
P56 1142-1119 - 5'-GTTTTCTAGCATGAATCACTCTGC NAT2-gene (3') 
P341N 342-373 442 
5'-ACCCAGCATCGACAATGTATTCC-
TGCCCTCA 
DdeI-site 341 nt (3')  
P87 480-499 421 5'-CCTGGACCAAATCAGGAGAG TaqI and DdeI-site 803 nt (5') 
P90 900-879 - 5'-ACACAAGGGTTTATTTTGTTCC (3') 
P85 368-386 192 5'-CTGGGTCTGGAAGCTCCTC (5') 
P86 559-540 - 5'-GGTGTTTCTTCTTTGGCAGG (3') 
 
Table 15: Restriction endonucleases for recognition of NAT2-mutations. 
Position Transition Restriction 
endonuclease 
Recognition 
sequence 
Preamplification 
with primers 
Cleavage-site (nt) 
Wildtype* 
Mutation 
Fragment-length 
(bp) Wildtype** 
Mutation 
- 442 
111 T>C TaqI T^CGA P100/P341 
111 262 180 
189 184 165 93 
191 G>A MspI C^CGG P100/P341 
96 277 165 
268 337 105 
282 C>T FokI 
GGATGnnnn
nnnnn^nnnn 
P100/P341 
- 442 
-2   153 220 163 59 
341 T>C DdeI C^TnAG P100/P341 
-2   153   341 188 163 59 32 
480 662 549 
481 C>T KpnI GGTAC^C P100/P56 
- 1211 
588 730 170 142 109 
590 G>A TaqI T^CGA P87/P90 
730 279 142 
776 297 124 
803 A>G DdeI C^TnAG P87/P90 
776   803 297 97 27 
856 925 286 
857 G>A BamHI G^GATCC P100/P56 
- 1211 
* First line, wild-type cleavage-site; second line, mutant cleavage-site 
** First line, wild-type fragment; second line, mutant fragment 
***n – A, C, T or G 
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2.3.2.6 Identification of NAT2 genotypes by continuous monitoring of fluorogenic 
hybridization probes 
 
Sixth polymorphic sites (111, 341, 481, 590, 803 and 857) of the NAT2 gene were analyzed, 
using rapid cycle DNA amplification with allele-specific fluorescent probes and melting curve 
analysis. The PCR primers for NAT2 genotyping are presented in Table 17. The hybridization 
probes were so designed that their melting temperatures (Tm) were similar to or a little higher 
than the Tm of the primers. The one probe was labelled with fluorescein (X) at the 3'-end, the 
second hybridization probe was labelled with LightCycler Red 640 (LC-Red 640) at the 5'-end. 
The two probes recognized adjacent sequences with the shorter probe lying over the mutation 
site. The probes were separated by one to five bases. Fluorescein was used as the donor 
fluorophore and blocked extension from the probe during PCR. LC-Red, with its 3'-end 
phosphorylated to block extension, was used as the acceptor of the FRET process. The greater 
stability of the longer anchor probe led to a loss of fluorescence as soon as the shorter probe 
melted off the template.  
 
Detection of the mutation 111T>C. 
For the detection of the 111T>C polymorphism, a 421-bp fragment was amplified with the 
primers NAT2-26F and NAT2-425R and detected with the hybridization probes 111S and 111A 
(Table 17). A 20-µl PCR mix contained 2 µl PCR-buffer, 1 µl 2 mmol/l dNTPs, 1.5 µl 50 mmol/l 
MgCl2, 0.4 µl of each of the primers, 0.2 µl of each of the hybridization probes, 1 µl DMSO, 0.6 
µl 1 mg/ml BSA, 1 U Taq-polymerase, 12.5 µl H2O, and 30 ng of genomic DNA.  
 
Detection of the mutation 341T>C. 
For the detection of the 341T>C polymorphism, a 421-bp fragment was amplified with the 
primers NAT2-26F and NAT2-425R and detected with the hybridization probes 341S and 341A. 
A 20-µl PCR mix contained 2 µl PCR-buffer, 1 µl 2 mmol/l dNTPs, 1.5 µl 50 mmol/l MgCl2, 0.4 
µl of each of the primers, 0.2 µl of each of the hybridization probes, 1 µl DMSO, 0.6 µl 1 mg/ml 
BSA, 1 U Taq-polymerase, 12.5 µl H2O, and 30 ng of genomic DNA.  
 
Detection of the mutation 481C>T. 
PCR with the primers P85 and P86 resulted in a 192-bp fragment, and the 481C>T 
polymorphism was detected with the hybridization probes Sensor 5 and Anchor 5. A 20-µl PCR 
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mix contained 2 µl PCR-buffer, 1 µl 2 mmol/l dNTPs, 2.5 µl 50 mmol/l MgCl2, 0.4 µl of each of 
the primers, 0.3 µl of each of the hybridization probes, 0.6 µl 1 mg/ml BSA, 1 U Taq-
polymerase, 12.3 µl H2O, and 30 ng of genomic DNA.  
 
Detection of the mutation 590G>A. 
For the detection of the 590G>A polymorphism, a 197-bp fragment was amplified with the 
primers P87 and P88 and detected with the hybridization probes Sensor 590 and Anchor 590. A 
20-µl PCR mix contained 2 µl PCR-buffer, 1 µl 2 mmol/l dNTPs, 2 µl 50 mmol/l MgCl2, 0.4 µl 
of each of the primers, 0.2 µl of each of the hybridization probes, 1 µl DMSO, 0.6 µl 1 mg/ml 
BSA, 1 U Taq-polymerase, 12 µl H2O, and 30 ng of genomic DNA.  
 
Detection of the mutation 803A>G. 
A 198-bp fragment was amplified with the primers P89 and P90 and detected with the 
hybridization probes Sensor 803A and Anchor 803. A 20-µl PCR mix contained 2 µl PCR-
buffer, 1 µl 2 mmol/l dNTPs, 2 µl 50 mmol/l MgCl2, 0.4 µl of each of the primers, 0.2 µl of each 
of the hybridization probes, 1 µl DMSO, 0.6 µl 1 mg/ml BSA, 1 U Taq-polymerase, 12 µl H2O, 
and 30 ng of genomic DNA.  
 
Detection of the mutation 857G>A. 
For the detection of the 857G>A polymorphism, a 198-bp fragment was amplified with the 
primers P89 and P90 and detected with the hybridization probes NAT2*857S and NAT2*857A. 
A 20-µl PCR mix contained 2 µl PCR-buffer, 1 µl 2 mmol/l dNTPs, 1 µl 50 mmol/l MgCl2, 0.4 
µl of each of the primers, 0.2 µl of each of the hybridization probes, 1 µl DMSO, 0.6 µl 1 mg/ml 
BSA, 1 U Taq-polymerase, 13 µl H2O, and 30 ng of genomic DNA.  
 
The temperature profiles used for the hybridization probes experiment are shown in Table 16. 
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Table 16: PCR conditions for the detection of mutations of NAT2 using LightCycler. 
PCR Reaction  Mutation  
Initial 
denaturation 
 Denaturation Annealing Elongation Number of 
cycles 
 
Melting 
curve, ramp 
rate, °C/s 
111T>C  95° 2 min  95° 3 s 56° 14 s 72° 20 s 60  0.1 
341T>C  95° 2 min  95° 3 s 56° 14 s 72° 20 s 45  0.15 
481C>T  95° 2 min  95° 3 s 60° 15 s 72° 15 s 42  0.15 
590G>A  95° 2 min  95° 3 s 60° 12 s 72° 18 s 45  0.15 
803A>G  95° 2 min  95° 3 s 60° 12 s 72° 18 s 58  0.05 
857G>A  95° 2 min  95° 3 s 50° 12 s 72° 20 s 47  0.1 
 
The differentiation of the PCR products was performed by the analysis of DNA melting curves 
in glass capillaries. First, DNA was denatured at 95°C, then maximal fluorescence was acquired 
by keeping the reaction at 40°C for 40 s. Melting curve data were generated by heating slowly to 
95°C and collected continuously during that time. As soon as the shorter probe melted off the 
template, FRET no longer took place.  
 
Table 17: Oligonucleotides used as PCR hybridization probes. 
Position Oligonucleotides Sequence 
NAT2-26F 5'- GACATTGAAGCATATTTTGAAAG Primers 
NAT2-425R 5'- TCCTTCCCAGAAATTAATTCTAG 
111S 5'- LC Red 640-CATGTTAAGGTTCTCAAAGGGAACAG 
111 
Probes 
111A 5'- CCAACTCCATGGCTTGCCCACAAT-Flu  
NAT2-26F 5'- GACATTGAAGCATATTTTGAAAG Primers 
NAT2-425R 5'- TCCTTCCCAGAAATTAATTCTAG 
341S 5'- CAGGTGACCACTIICGGCAGGAATTACAT-Flu 
341 
Probes 
341A 5'- LC Red 640-TCGATGCTGGGTCTGGAAGCTCCTCCC 
Primer 85 5'- CTGGGTCTGGAAGCTCCTC Primers 
Primer 86 5'- GGTGTTTCTTCTTTGGCAGG 
Sensor 5 5'- LC Red 640-TCTGGTACCTGGACCAAATCAGGA 
481 
Probes 
Anchor 5 5'- GCATTTTCTGCTTGACAGAAGAGAGAGGA-Flu 
Primer 87 5'- CCTGGACCAAATCAGGAGAG Primers 
Primer 88 5'- GCAAGGAACAAAATGATGTGG 
Sensor 590 5'- TTGAACCTCAAACAATTGAA-Flu 
590 
Probes 
Anchor 590 5'- LC Red 640-TTTGAGTCTATGAATACATACCTGCAGACGTCT 
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Primer 89 5'- GTGGGCTTCATCCTCACCTA Primers 
Primer 90 5'- ACACAAGGGTTTATTTTGTTCC 
Sensor 803A 5'- TTGAAGAAGTGCTAAAAATATTTAAGA-Flu 
803 
Probes 
Anchor 803 5'- LC Red 640-TTCCTTGGGGCGAAATCTCTGGC 
Primer 89 5'- GTGGGCTTCATCCTCACCTA Primers 
Primer 90 5'- ACACAAGGGTTTATTTTGTTCC 
NAT2*857S 5'- LC Red 640-CAAACCTGGTGATGGATCCCT 
857 
Probes 
NAT2*857A 5'- TTCCTTGGGGAGAAATCTCGTGC-Flu 
 
 
2.4 Statistical analysis 
All information about patients was collected in a databank. The databank was constructed with 
the Excel statistical program. Data were transferred to SPSS 10.0 and with this program all 
statistical tests were analyzed. All values given with 95% confidence interval were calculated 
with the χ2 test. All results with a two-sided P value ≤0.05 were regarded as statistically 
significant. The comparison of the frequencies of single mutations, alleles and genotypes 
between different populations was performed with the statistical program Intercooled Stata 7.0. 
Expected genotype frequencies were calculated from allele frequencies with the Hardy-
Weinberg equation (1 = p2 + 2pq + q2). 
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3 Results 
3.1 Frequencies of CYP1A1 point mutations and alleles 
Seven point mutations of CYP1A1 were detected. The data are presented in Table 18. The most 
frequent mutation was -4335G>A, which appeared in 25.8% of alleles. The frequencies of other 
point mutations were as follows: m1 (3801T>C) appeared in 9.8%, m2 (2455A>G) in 5%, m4 
(2453C>A) in 2.5%, m6 (-3219C>T) in 6.0% and m7 (-3229G>A) in 2.9% of alleles. Mutation 
m3 (3205T>C) did not occur. 
The frequencies of point mutations and alleles of CYP1A1 are shown in Table 18. 
 
Table 18: CYP1A1 mutation and allele frequencies in the Russian sample, n=325. 
Nucleotide-position (nt) 
m1 m2 m3 m4 m5 m6 m7 
CYP1A1 
allele 
3801 2455 3205 2453 -4335 -3219 -3229 
n % 95% C. I. 
*1A(wt) T A T C G C G 364 56.0 52.1-59.9 
*1B T A T C G T G 39 6.0 4.3-8.1 
*1C T A T C G C A 0 0.0 0.0-0.6 
*1D T A T C A C G 149 22.9 19.7-26.4 
*1E T A T C A C A 19 2.9 1.8-4.5 
*2A C A T C G C G 30 4.6 3.1-6.5 
*2B C G T C G C G 33 5.1 3.5-7.1 
*4 T A T A G C G 16 2.5 1.4-4.0 
n 64 33 0 16 168 39 19 650   
% 9.8 5.0 0.0 2.5 25.8 6.0 2.9  100.0  
95% C. I.           
Min. 7.7 3.5 0.0 1.4 22.5 4.3 1.8    
Max. 12.4 7.1 0.6 4.0 29.4 8.1 4.5    
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3.2 Genotype frequencies of CYP1A1 
Table 19: Genotypes of CYP1A1 which occurred in this study 
Genotype n % 95% C. I. Expected, %* 
*1A/*1A 106 32.7 24.5-38.0 31.5 
*1A/*1B 21 6.6 4.0-9.7 6.8 
*1A/*1D 81 25.0 20.3-30.0 25.7 
*1A/*1E 11 3.4 1.7-6.0 3.3 
*1A/*2A 17 5.3 3.1-8.2 5.3 
*1A/*2B 16 5.0 2.8-7.9 5.8 
*1A/*4 6 1.8 0.7-3.9 2.9 
*1B/*1D 10 3.0 1.5-5.6 2.8 
*1B/*1E 2 0.6 0.07-2.2 0.4 
*1B/*2A 1 0.3 0.01-1.7 0.7 
*1B/*2B 2 0.6 0.07-2.2 0.7 
*1B/*4 3 0.9 0.2-2.7 0.4 
*1D/*1D 14 4.3 2.4-7.1 5.3 
*1D/*1E 6 1.8 0.7-3.9 1.4 
*1D/*2A 8 2.5 1.1-5.0 2.2 
*1D/*2B 12 3.8 1.9-6.4 2.4 
*1D/*4 4 1.2 0.3-3.1 1.2 
*2A/*2B 2 0.6 0.07-2.2 0.6 
*2A/*4 2 0.6 0.07-2.2 0.3 
*2B/*4 1 0.3 0.01-1.7 0.3 
Sum 325 100.0   
* Expected genotype frequencies are calculated from the frequencies of the single alleles (Table 18) according to the Hardy-
Weinberg law. 
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3.3 Allele frequencies of CYP2D6 
We have investigated the functionally important alleles which occur most frequently among 
Caucasians: CYP2D6*1, *3, *4, *5 (gene deletion), *6, Asiatic allele *10, and allele duplications 
*1x2, *2x2. The data are presented in Table 20. The frequency of the gene-duplication of the 
highly active CYP2D6 wild-type allele *1x2 was 1.7% (0.8-3.2), that of the duplication of the 
slightly active allele *2x2 was 1.0% (0.2-3.0). The duplication of the deficient allele *4 was not 
found in the Russian sample. We did not differentiate alleles with slightly decreased activity, 
such as *2, *9 and *10. 
 
Table 20: The frequencies of CYP2D6 alleles in the Russian sample, n=290. 
Nucleotide position (nt) 
Allele 
188 1749 1795 1934 2637 4268 
n % 95 % C. I. 
*1 C G T G A G 411 70.8 67.0-74.5 
*3 C G T G Del G 6 1.0 0.4-2.2 
*4 T C/G T A A C 105 18.2 15.1-21.5 
*6 C G Del G A G 7 1.2 0.5-2.5 
*10 T C T G A C 24 4.2 2.7-6.1 
*1x2 (CYP2D6*1 Duplication) 10 1.7 0.8-3.2 
*2x2 (CYP2D6*2 Duplication) 3 0.5 0.1-1.5 
*4x2 (CYP2D6*4 Duplication) 0 0.0 0.0-0.6 
*5 (CYP2D6 Deletion) 14 2.4 1.3-4.0 
Total  580 100.0  
 
 
3.4 Frequencies of CYP2D6 genotypes 
Genotype frequencies and distribution of groups with different metabolic activity in the Russian 
sample are shown in Table 21. 
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Table 21: Genotype frequencies of CYP2D6. 
Genotype n % 95% C. I. Expected %* 
3 active genes (UM/EM) 10 3.4 1.7-6.3 2.6 
*1x2/*1 10 3.4 1.7-6.3 2.6 
2 active genes (EM/EM, EM/IM, 
IM/IM, UM/PM) 
168 57.9 52.0-63.7 56.5 
*1/*1 148 51.0 45.1-56.9 50.1 
*2x2/*4 3 1.0 0.2-3.0 0.2 
*1/*10 16 5.5 3.2-8.8 5.9 
*10/*10 1 0.3 0.0-1.9 0.2 
1 active gene (EM/PM, IM/PM) 95 32.8 27.4-38.5 34.2 
*1/*3 4 1.4 0.4-3.5 1.5 
*1/*4 70 24.1 19.3-29.5 25.8 
*1/*5 10 3.4 1.7-6.3 3.6 
*1/*6 5 1.7 0.6-4.0 1.8 
*4/*10 6 2.1 0.8-4.5 1.5 
0 active genes (PM/PM) 17 5.9 3.5-9.2 5.0 
*3/*4 2 0.7 0.1-2.5 0.4 
*4/*4 9 3.1 1.4-5.8 3.3 
*4/*5 4 1.4 0.4-3.5 0.9 
*4/*6 2 0.7 0.1-2.5 0.4 
Sum 290 100.0   
* Expected genotype frequencies are calculated from the frequencies of the single alleles (Table 20) according to the Hardy-
Weinberg law. 
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3.5 Frequencies of CYP2D6 genotypes, according to gender 
The sample of Russian study participants consisted of 152 men and 138 women. The frequencies 
of UMs and EMs were slightly higher in women – 3.7% of UM and 60.3% of EM in comparison 
to 3.3% UM and 55.9% EM in men (n. s.). The data found in different gender groups is 
presented in Table 22. 
 
Table 22: Frequencies of CYP2D6 genotypes in 152 men and 138 women in a Russian 
sample. 
Men  Women CYP2D6 
genotype n %  n % 
UM 5 3.3  5 3.7 
EM 85 55.9  83 60.3 
IM 53 34.9  42 30.6 
PM 9 5.9  8 5.4 
n 152 100.0  138 100.0 
 
 
3.6 Frequencies of CYP2D6 genotypes, according to age 
The age of participants ranged from 14 to 77 years. They were assigned to three different age 
groups. Ninety-one individuals were under 30 years and 150 were older than 40 years. The 
distributions of CYP2D6 genotypes among the three different age groups are presented in Table 
23. 
 
Table 23: Frequencies of CYP2D6 genotypes in different age groups in a Russian sample. 
Age group 
< 30 30-40 > 40 
CYP2D6 
genotype 
n % n % n % 
UM 2 2.2 2 4.1 6 4.0 
EM 54 59.3 23 46.9 91 60.4 
IM 30 33.0 22 44.9 43 28.9 
PM 5 5.5 2 4.1 10 6.5 
n 91 100.0 49 100.0 150 100.0 
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3.7 Frequencies of NAT2 point mutations and alleles  
In this study seven out of eight tested point mutations could be allocated to eight different allelic 
variants. The 341C>T transition was the most frequent mutation in Russians, it appeared in 
42.6%. The 111T>C mutation occurred in only 0.3% of individuals. We found neither the 
specific Black-African 191G>A mutation nor unknown haplotypes. The frequencies of the 
investigated point mutations are presented in Table 24. There were two alleles which led to 
rapid-acetylation activity (NAT2*4 and *12), and six alleles (NAT2*5A, *5B, *5C, *6A, *6D and 
*7B) which were associated with slow acetylation activity. 
 
Table 24: Frequencies of NAT2 alleles and point mutations in 325 healthy Russian 
volunteers and patients without any known malignant disease. 
Nucleotide position (nt) NAT2 
allele 111 191 282 341 481 590 803 857 
Pheno-
type n % 
95% C. I. 
*4(wt) T G C T C G A G Rapid 145 22.3 19.2-25.7 
*5A T G C C T G A G Slow 15 2.3 1.3-3.8 
*5B T G C C T G G G Slow 242 37.3 33.5-41.1 
*5C T G C C C G G G Slow 17 2.6 1.5-4.2 
*6A T G T T C A A G Slow 208 32.0 28.4-35.7 
*6D C G T T C A A G Slow 2 0.3 0.04-1.1 
*7B T G T T C G A A Slow 19 2.9 1.8-4.5 
*12A T G C T C G G G Rapid 4 0.6 0.2-1.6 
*14A T A C T C G A G ? 0 0.0 0.0-0.6 
*14B T A T T C G A G ? 0 0.0 0.0-0.6 
n 2 0 223 277 256 204 264 19     
% 0.2 0.0 17.9 22.2 20.6 16.4 21.2 1.5     
95 % C. I.             
Min. 0.02 0.0 15.8 20.0 18.4 14.4 19.0 0.9     
Max. 0.6 0.3 20.2 24.7 22.9 18.6 23.6 2.4     
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3.8 Frequencies of NAT2 genotypes 
Table 25 shows the distribution of NAT2 genotypes among Russians. One hundred and thirty one 
subjects had a genotype associated with fast acetylation (40.3%). Eighteen individuals (5.5%) 
had the homozygous rapid-acetylator genotype (NAT2*4/*4 and NAT2*4/*12), and 112 subjects 
were heterozygous for the alleles NAT2*4 or *12A which encode a rapid phenotype. The number 
of slow acetylators, coded by alleles NAT2*5A, *5B, *5C, *6A, *6D, and *7B, amounted to 
59.7%. The most common genotypes leading to slow acetylation were NAT*5B/*6A (25.3%) and 
*5B/*5B (13.6%). The genotype combinations *4/*12A, *5B/*12A, *5A/*7B, and *7B/*7B were 
found only once each. The genotype frequencies were in good agreement with the expected 
values as calculated with the Hardy-Weinberg equilibrium from the frequencies of single alleles 
(Table 24). 
Table 25: Distribution of NAT2 genotypes among 325 Russian individuals. 
NAT2 genotype N % 95% C. I. Expected %* 
*4/*4 17 5.3 3.1-8.2 4.9 
*4/*5A 2 0.6 0.07-2.2 1.0 
*4/*5B 52 16.0 12.2-20.5 16.6 
*4/*5C 3 0.9 0.2-2.7 1.2 
*4/*6A 47 14.5 10.8-18.8 14.3 
*4/*7B 6 1.8 0.7-3.9 1.3 
*4/*12A 1 0.3 0.01-1.7 0.3 
*5B/*12A 1 0.3 0.01-1.7 0.4 
*6A/*12A 2 0.6 0.07-2.2 0.4 
Not found -    
Sum rapid 131 40.3 34.9-45.9 40.4 
*5A/*5B 6 1.8 0.7-3.9 1.7 
*5A/*6A 6 1.8 0.7-3.9 1.5 
*5A/*7B 1 0.3 0.01-1.7 0.1 
*5B/*5B 44 13.6 10.0-17.6 13.9 
*5B/*5C 7 2.2 0.9-4.4 1.9 
*5B/*6A 82 25.3 20.6-30.3 23.9 
*5B/*7B 6 1.8 0.7-3.9 2.1 
*5C/*6A 5 1.5 0.5-3.6 1.7 
*5C/*7B 2 0.6 0.07-2.2 0.2 
*6A/*6A 30 9.3 6.3-12.9 10.2 
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*6A/*6D 2 0.6 0.07-2.2 0.4 
*6A/*7B 2 0.6 0.07-2.2 1.9 
*7B/*7B 1 0.3 0.01-1.7 0.1 
Not found -    
Sum slow 194 59.7 54.1-65.1 59.6 
Total 325 100.0   
* Expected genotype frequencies are calculated from the frequencies of the single alleles (Table 
24) according to the Hardy-Weinberg law. 
 
3.9 Identification of N-acetyltransferase 2 genotypes by continuous monitoring of 
fluorogenic hybridization probes 
127 samples were checked for sixth mutations at the positions 111, 341, 481, 590, 803 and 857 
of NAT2 which allow detecting all known genotypes of NAT2 in Caucasians. We used a new 
technique which combines a microvolume fluorimeter with a rapid temperature cycler 
(LightCycler). Homogenous curves were observed for wild-type and mutant alleles, whereas 
heterogeneous curves resulted from the simultaneous presence of both alleles.  
The melting temperatures of wild-type alleles and mutant alleles are present in Table 26. When 
hybridization probes formed a perfect match with the target, this resulted in a comparatively 
stable complex and, consequently, in a high Tm. As expected, a lower Tm was observed in the 
case of a mismatch. Samples containing both alleles (heterozygous) displayed 2 melting peaks at 
exactly the same temperatures as the respective homozygous samples. Negative controls without 
added template did not show any signal. 
 
Table 26: Melting temperature of wild-type and mutant alleles of NAT2. 
Position  Tm (wild type) Tm (mutation) 
111  64.0°C 58.0°C 
341  59.0°C 65.0°C 
481  61.5°C 68.0°C 
590  47.0°C 54.7°C 
803  49.5°C 46.5°C 
857  61.5°C 57.5°C 
 
The melting peaks derived from these data are shown below. 
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Figure 23: Detection of the mutation 111T>C. 
 
Figure 24: Detection of the mutation 341T>C. 
 
 
 
Figure 25: Detection of the mutation 481C>T. 
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Figure 26: Detection of the mutation 590G>A. 
 
 
 
Figure 27: Detection of the mutation 803A>G. 
 
 
 
Figure 28: Detection of the mutation 857G>A. 
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4 Discussion 
Population frequencies of many pharmacogenetics traits have been shown to depend on ethnic 
specificity. This was the first study which investigated allele frequency distributions of drug and 
xenobiotic-metabolizing enzymes in a Russian sample. The number of investigated samples was 
large enough to find even rare alleles of polymorphic genes. 
 
4.1 Interethnic variability of enzymes of phases I and II 
In order to avoid the accumulation of harmful xenobiotics in cells, living organisms have 
developed ways for their elimination. Multiple xenobiotic metabolizing enzymes with different 
and partially overlapping catalytic properties play a key role in the elimination process. These 
enzymes are encoded by superfamilies of genes, the evolution of which has enabled different 
species to survive in different habitats and to take advantage of diets containing certain harmful 
xenobiotics. As a result of this evolutionary process, species have achieved capacities for 
metabolizing which are appropriate for their survival, but which may differ considerably from 
those of other species. This evolutionary process may also explain the interethnic and 
interindividual variability of drug metabolism in humans.  
 
4.1.1 Genotype frequencies of CYP1A1 
The frequency of the known seven cytochrome P450 1A1 (CYP1A1) gene mutations was 
investigated in 325 Russians. The mutations m1 (6235T>C) and m2 (4889A>C) were not 
significantly different from the German population: m1: 9.8% of alleles and 7.7% (p=0.1), m2: 
5.0% of alleles and 2.7% (p=0.06) in Russians and Germans, respectively, the frequency of m4 
(2453C>A) did differ in the two populations – 2.5% and 3%, respectively (German data from 
Cascorbi et al. (Cas96c)). M2 was found to be exclusively linked with the m1 forming allele 
CYP1A1*2B. CYP1A1 mutations tended to be more frequent in the Russian sample than in other 
Caucasian groups, but were rarer than in a Turkish population (m1 – 18.1% (p=0.0004), m2 – 
8.9% (p=0.04), m4 – 5.7% (p=0.007), according to Aynacioglu et al. (Ayn98)) or in the Far East 
(m1 appears with the frequency of 33.2% in Japanese, p<0.0001 (Nak91)). The frequencies of 
the CYP1A1 high-activity alleles, CYP1A1*2A and CYP1A1*2B, were 4.6% (3.1%-6.5%) and 
5.1% (3.5%-7.1%), respectively. The frequency of the CYP1A1*2A allele was comparable with 
the frequency in the Polish population, namely 4.5% (Mro97). The frequencies of  m5, m6 and 
m7 mutations in different populations are not available up to now. 
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4.1.2 Genotype frequencies of CYP2D6 
The frequencies of CYP2D6 genotypes vary between populations. The deficient allele *4 is the 
allele with the highest ethnic variability. The virtual absence of the common "white" *4 allele in 
East Asian populations explains the very low prevalence of the PM trait in these people. 
CYP2D6*5 occurs in Orientals as frequently as in Caucasians and Africans and accounts for the 
few poor metabolizers in Orientals (Joh91). The allele frequency of CYP2D6*10 is high (50%) 
in the Oriental population and low (5%) in Caucasians (Arm94, Joh94). Genotyping of African 
populations (Mas93, Mas96, Akl96) revealed the absence of the CYP2D6*3 allele and the low 
prevalence of CYP2D6*4 thus explaining the low prevalence of poor metabolizers in these 
populations. Possibly, allele *4 appeared in Caucasoids only after their separation from the 
Asian/Amerindian group about 35.000 years ago. The allele *3 appears to be rare except in 
Whites, whereas the deletion allele *5 occurs with comparable frequency in most populations. 
The allele *17 was found exclusively in African populations (Mas96) and was postulated to be 
the basis of the diminished debrisoquine hydroxylase activity in these populations. 
In this study, only those population frequencies of allelic variants of the highly polymorphic 
enzyme CYP2D6 have been determined which are functionally most important. We did not 
investigate the frequency of allele *2 (with the exception of the allele *2 duplication), which has 
been shown to have only slightly decreased activity in comparison with allele *1 (Sac97). In the 
case of allele duplications the determination of the duplicated allele (*2x2 or *4x2) is clinically 
important in a correct prediction of the metabolic capacity to avoid misclassification of *4 
duplication as ultrarapid allele. The frequencies of alleles *9 and *7 were relatively low in 
Caucasians in  previous studies (Sac97), so we did not include these and more rare alleles, such 
as *8, *11, *12, *14, *15 in this study. 
The frequencies of the defective alleles *3, *4, *5 and *6 found in our study were comparable 
with those found in earlier studies of Caucasians (Sac97, Lea98). The frequency of allele 
duplications in Russians (2.2%) was not significantly different from other Caucasians: 
duplications were found in 2.0% of Germans (Sac97), in 1.9% of Frenchmen (Leg98), and in 
1.0% of the Swedish population (Dah95). In contrast, a high frequency of duplicated alleles was 
described in black Ethiopians and Saudi Arabians (Table 27). 
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Table 27: The frequency of deficient and duplicated alleles of CYP2D6 in different 
populations. 
Allele frequency (%) 
Population n 
*3 *4 *5 *6 *MxN 
Reference 
Japanese 256 nf* 0.8 4.1 0.5 nd** Chi99 
Koreans 152 nd nd nd nd 0.3 Roh96 
Chinese 113 nd nd nd nd 1.3 Joh94 
Germans 589 2.0 21.0 2.0 0.9 2.0 Sac97 
Polish 145 2.1 23.1 0.7 nd nd Gaw99 
French 265 nd nd nd nd 1.9 Leg98 
Russians 290 1.0 18.2 2.4 1.2 2.2 This study 
South-Spanish 217 nd 12.0 3.9 nd 3.5 Agu95 
North-Spanish 147 nd 20.0 3.4 nd 5.1 Bern97 
Turkish 404 nf 11.0 1.0 nf 6.0 Ayn99 
West-Africans 326 nf 6.3 6.0 nf 1.6 Gri99 
Saudi Arabians 101 nd 3.5 1.0 nd 10.0 McL97 
Black Ethiopians 122 nd nd nd nd 16.0 Akl96 
Black Tanzanians 106 nf 6.3 6.0 nf nd Wen99 
* not found  
** not detected 
 
4.1.3 Genotype frequencies of NAT2 
The prevalence of slow acetylator genotypes in the Russian sample was found to be similar to 
other Caucasian populations. The frequencies of slow acetylator genotypes vary considerably 
among ethnic groups. Genotyping data of the common NAT2 alleles helps us to understand the 
molecular history of the acetylation polymorphism (Table 28). Two groups can be distinguished 
by the prevalence of the mutations 341T>C/481C>T (NAT2*5A, B, C) and 857G>A (NAT2*7A, 
B): in Caucasians and Africans the frequencies of alleles *5 are high and the frequencies of 
alleles *7 are low whereas it is just opposite in the Japanese, Chinese, and in other Asian 
populations. Thus, the difference in the prevalence of the slow acetylator phenotype between 
Caucasians/Africans and Asian populations is mostly the result of the low prevalence of the 
NAT2*5 alleles in Asians. Asian populations show high frequencies of the wild-type allele 
NAT2*4 (44 to 79%) in comparison with other ethnic groups (6 to 24%). The frequency in 
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Hispanics is intermediate between the Caucasians/Africans and the Asian groups. The data is 
consistent with the theory that the acetylation polymorphisms have an ancient and common 
African origin, which dates back to the period before the spreading of human populations in the 
paleolithic. The practical absence of the NAT2*12 and NAT2*14 alleles in Caucasians and the 
high frequency of 191G>A in Africans suggests that these mutations appeared after the 
African/Non-African split about 90 000 years ago. 
 
Table 28: Comparison of allele frequencies (%) of NAT2 between different ethnic groups. 
Population n *4 *5A *5B *5C *6A *6D *7B *12A *14B Reference 
African 117 9.4 1.3 28.2 6.4 24.4 nd* 1.3 12.0 7.3 Del96 
German 1088 23.4 2.5 40.9 2.6 28.4 nd 2.1 0.1 0.1 Cas95 
Turkish 303 23.1 1.3 35.6 4.8 30.5 nd 4.5 0.2 nf** Ayn97 
Polish 248 22.0 5.2 33.1 6.0 30.0 nd 3.4 0.2 nf Mro96 
Russian 325 22.3 2.3 37.3 2.6 32.0 0.3 2.9 0.6 nf This study 
Japanese 145 68.6  2.4§  19.3 nd 9.7 nd nf Oku97 
Chinese 187 51.0  7.5§  32.0 nd 10.0 nd nd Lee98 
Hispanic 137 41.6  31.4§  16.8 nd nd nd nd Mar98 
*- not detected, **- not found 
§- alleles of the group *5 were not differentiated 
 
4.2 Individual pharmacotherapy adjusted to genotype 
Metabolism of many drugs influences their pharmacological and toxicological effects. One of the 
major causes of interindividual variation of drug effects is genetic variation of drug metabolism. 
Polymorphisms, which cause decreased, increased, or lacking enzyme expression or activity by 
multiple molecular mechanisms, are generated by mutations in the genes for drug-metabolizing 
enzymes. 
The type and prevalence of allelic variants present in a population will influence the 
pharmacological and toxicological effects of drugs, toxins and carcinogens and lead to 
interindividual and interethnic differences. 
The observation that individuals who are genetically deficient in a particular P450 enzyme are 
poor metabolizers of one or several drugs illustrates a very important principle; namely that the 
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rate of elimination of drugs can be largely determined by a single P450 enzyme. This 
observation seems to contradict the fact that P450 enzymes have broad and overlapping substrate 
specificities. The explanation of this evident paradox lies in the fact that although more than one 
human P450 enzyme can catalyze the biotransformation of xenobiotics, their affinities may be 
markedly different. Consequently, xenobiotic biotransformation in vivo, where only low 
substrate concentrations are usually achieved, is often determined by the P450 enzyme with the 
highest affinity for the xenobiotic. For example, the N-demethylation of diazepam and the 5-
hydroxylation of omeprazole are both catalyzed by two P450 enzymes, namely CYP2C19 and 
CYP3A4. However, these reactions are catalyzed by CYP3A4 with such low affinity that the N-
demethylation of diazepam and the 5-hydroxylation of omeprazole in vivo appear to be 
dominated by CYP2C19 (Kat94). Similarly, tolbutamide is metabolized by both CYP2C9 (70%) 
and CYP2C19 (30%) (Ino97, Wes00, Ven98, McG00) and ibuprofen by CYP2C9 (90%) and 
CYP2C19 (10%) (Leem93, Hamm97). The most important drug metabolizing P450 enzymes are 
presented in Figure 29. 
 
CYP3A4/-3A5
Amitryptiline
Carbamazepine
Clarithromycin
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Lidocaine
Midazolam
Nifedipine
CYP2D6
Amitriptyline
Codeine
Haloperidol
Imipramine
Metoprolol
Nortriptyline
Propafenone
CYP2C9
Diclofenac
Ibuprofen
Losartan
Phenytoin
Tolbutamide
CYP2C19
Diazepam
Citalopram
Omeprazole
Proguanil
CYP1A2
Clozapine
Imipramine
Caffeine
Paracetamol
PhenacetinCYP2E1
Chlorzoxazone
Enflurane
Halothan
Caffeine
Theophylline
 
Figure 29: The role of different P450 enzymes in metabolism of drugs (Ben95). 
 
Sometimes two or more P450 enzymes contribute equally to the metabolism of a single 
compound. In the metabolism of propranolol for example, CYP2D6 oxidizes the aromatic ring to 
give 4-hydroxypropranolol, CYP1A2 mediates ethoxyresorufine O-deethylation, and CYP2C19 
oxidizes the isopropranolamine side chain. Consequently, changes in either CYP2D6 or 
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CYP1A2 or CYP2C19 do not markedly affect the disposition of propranolol. Three human P450 
enzymes, CYP1A2, CYP2E1, and CYP3A4, can convert the commonly used analgesic, 
acetaminophen, to its hepatotoxic metabolite, N-acetylbenzoquinoneimine. It is also possible that 
a single P450 enzyme catalyzes two or more metabolic pathways of the same drug. 
 
 
4.2.1 Genetic susceptibility to adverse drug reactions 
Possible risk factors for drug toxicity or inefficacy are the age of the patient, concomitant 
diseases such as liver or renal diseases, lifestyle habits such as smoking or alcohol consumption, 
or drug-drug interactions. Hereditary factors that affect the kinetic and dynamic parameters of 
various drugs are of great importance in the determination of the individual risk. Genetic 
polymorphisms in the genes for drug metabolizing enzymes, drug transporters and drug receptors 
are related to individual variability in the efficacy and toxicity of drugs (Mey91, Ing99, Evan99, 
Ros00). 
Genetic polymorphisms of these enzymes give rise to distinct subgroups in the population that 
differ in their ability to perform certain drug biotransformation reactions. In specific sub- 
populations undergoing treatment, this can lead to a variety of consequences, such as therapeutic 
failure, adverse effects and toxicity, which are often difficult to foresee. The incidence of serious 
and fatal adverse drug reactions has been found to be extremely high among patients; adverse 
drug reactions caused about 100 000 deaths in the USA in 1994 (Laz98). 
Genetic analysis of drug metabolizing enzymes is clinically important for determining the 
appropriate dosage of certain drugs; thus it prevents therapeutic failures, adverse effects and 
toxicity. Knowing the genotype of a patient might help improve drug efficacy and reduce 
toxicity - by selecting the right drug for the right patient. When mutations result in null alleles 
(no catalytic activity), drugs may reach toxic levels if given in standard doses. Some typical 
adverse drug reactions caused by CYP450 polymorphisms are presented in Table 29. 
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Table 29: Cytochrome P450 enzyme gene polymorphism and possible adverse drug 
reactions. 
Adverse reaction P450 
enzyme 
Frequency of 
polymorphism 
Drug 
In slow metabolizers In fast metabolizers
Reference
CYP1A2 5-10% deficient Antipsychotics  Tardive dyskinesia Bas00 
Warfarin Haemorrhage  Ait99 2-3% 
(homozygous) Tolbutamide Hypoglycaemia  Mine98 
Phenytoin Phenytoin toxicity  Kid99 
CYP2C9 
15-20% 
(heterozygous) Losartan Decreased 
antihypertensive effect
 Mine98 
CYP2C19 2-4% (Caucasians ) 
10-25% (Asians) 
(homozygous) 
Diazepam Prolonged sedation  Mey00 
Antiarrhythmics Arrhythmias  Mey00 5-10% (poor 
metabolizers) Beta-Blockers Bradycardia   
Tricyclic 
antidepressants 
Toxicity Inefficacy Mey00 
CYP2D6 
1-10% (ultrarapid 
metabolizers) 
Opioids Inefficacy of codeine 
as analgesic 
Narcotic side-
effects, dependence
Mey00 
 
 
In patients with a defective CYP variant, genotyping could help select drugs that do not depend 
upon the defective CYP for excretion. Because there are various CYP isoforms, individuals who 
poorly metabolize one drug may have normal metabolism of another. 
Average dose recommendations for drugs with genetically polymorphic elimination and 
deactivation may be considered as a compromise to achieve sufficiently safe and effective 
treatment in all patients, including PMs and EMs. Thus, these standard dosages are probably 
lower than optimal for the EM group, and higher than optimal for the PM group. 
It is certainly very useful to know the patient's genotype; nevertheless, drug metabolism is 
complex and might be complicated by various factors: (1) multiple mutations and alleles with 
varying effects (> 50 alleles for CYP2D6 alone), (2) greatly varying allele frequencies for each 
CYP isoform in different populations, (3) effects of heterozygocity on drug metabolism, (4) 
possible interaction of one drug with more than one CYP isoform, (5) unexpected drug-drug 
interactions in a patient carrying null alleles in one CYP isoform through inhibition of other CYP 
isoforms. 
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1.1.4 Impact of the CYP2D6 genotype on drug treatment 
The clinical impact of polymorphisms of CYP2D6 is a subject of great interest with special 
attention paid to cardiovascular and neuroactive drugs, because many CYP2D6 substrates belong 
to these classes of drugs. CYP2D6 enzyme activity ranges from relatively low to ultra-rapid. 
Allele frequencies of CYP2D6 which lead to poor metabolizer status or extensive metabolizer 
status for many drugs mainly metabolized by CYP2D6 range from 1% to 10% in different 
populations. Generally, poor metabolizers and extensive metabolizers differ between 2- and 5-
fold in their capacities to metabolize CYP2D6 substrates; hence PMs obtain the same steady-
state serum level as EMs with only 20-50% of the doses (Bros93). 
The CYP2D6 genotype has been shown to predict the clearance of antidepressants (Spi97, Car96, 
Ham96) as well as that of neuroleptics (Jer96). Numerous case reports and clinical studies have 
demonstrated that the CYP2D6 polymorphisms could lead to a higher propensity to develop 
adverse reactions at conventional doses. It has been shown that individuals who lack functional 
CYP2D6 genes metabolize certain CYP2D6 substrates, particularly antidepressants and 
neuroleptics, at a lower than normal rate. Thus, PMs may be treated with unnecessarily high 
doses of neuroleptics, resulting in a higher number of side effects which may worsen the patient's 
compliance with the treatment (Sha93). Antipsychotics have a very narrow therapeutic window. 
Plasma concentrations above the therapeutic level only increase the risk of extrapyramidal side 
effects without further increasing the antipsychotic activity (Han81). Adverse effects due to 
elevated drug plasma levels would be expected to occur more frequently when the drug 
clearance depends entirely on CYP2D6. Sometimes decreased drug effects or therapeutic failure 
occur at normal antidepressant doses in ultrarapid metabolizers, as it has been described in the 
rare subjects with 13 CYP2D6 copies on one allele. They synthesized substantially higher 
amounts of metabolites of nortriptyline than those carrying fewer active CYP2D6 genes (Dal98). 
Antiarrhythmics have pro-arrhythmic effects in 10% to 20% of patients, and high concentration 
of these drugs in plasma has been identified as a predisposing factor. As there is a correlation 
between antiarrhythmic activity and plasma concentration for most antiarrhythmics, drug dosage 
should be adjusted to achieve and maintain steady-state concentrations in the therapeutic range. 
A patient with cardiac failure, renal and/or liver failure who also happens to be a PM will be at a 
high risk of developing side effects. Vomiting and arrhythmias during treatment with 
propafenone (Bot94) and mexiletine (Lle93) have been seen to occur only in PMs and were 
attributed to elevated plasma drug concentration as a consequence of lower metabolic rate. 
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On the one hand, PMs are at increased risk of accumulating drugs and suffering from drug-
related toxicity, on the other hand they might experience therapeutic failure with prodrugs that 
need metabolization to achieve pharmacological activity. A lack of CYP2D6 enzyme activity 
should result in reduced efficacy when prodrugs requiring activation by CYP2D6 are used. An 
absence of the analgetic effect of codeine in PMs due to their inability to form morphine has 
been described by Poulsen et al. (Pou96). At the same time, severe abdominal pain, a typical 
adverse effect of morphine, was observed in ultra-rapid metabolizers treated with codeine 
because of extensive formation of morphine (Dal97). 
Cytochrome P450 2D6 is a drug-metabolizing enzyme with a limited metabolizing capacity even 
in EMs. Due to its saturation during the first pass, it metabolizes drugs such as propafenone and 
imipramine in a dose-dependent manner (Sid87, Bros88). CYP2D6 is also the site of a number of 
drug interactions (Wag87). Substrates with a very high affinity to the enzyme such as 
propafenone bind strongly to it and inhibit the metabolism of compounds with lower affinity. 
These drug interactions occur in extensive as well as in poor metabolizers and may lead to 
clinically important effects, as has been documented for the combination of certain neuroleptics 
with antidepressants (Nel80). 
The intermediate active CYP2D6*10 allele occurs rather frequently in Oriental populations. It 
results in a certain metabolic insufficiency, the clinical consequences of which are reflected in 
the literature: the lower doses of neuroleptics used in Asians compared with Caucasians (Lin83), 
the higher plasma haloperidol concentration and a higher prolactin response to haloperidol 
(Lin88), the impaired formation of morphine from codeine (Tse96), and the disposition of the 
Beta-adrenoreceptor antagonist propranolol (Lay95). Guided by their practical observations of 
drug efficacy and side effects, clinicians in Oriental populations have been prescribing 
antipsychotics at lower doses than physicians in Caucasian populations; it is now postulated that 
the differences in drug metabolism resulted in different prescribing habits (Lin91). 
Since the therapeutic efficacy and the adverse effects of many drugs depend on CYP2D6 
activity, genotyping of CYP2D6 may become a part of routine laboratory examination. The 
increasing knowledge of the CYP2D6 phenotype and genotype status in different populations 
could be used to design genotype-based dose-finding studies. Some steps have already been 
taken in this direction. Kirchheiner et al. (Kir01) suggested preliminary genotype-based dose 
recommendations for antidepressants which are metabolized by CYP2D6 and CYP2C19. 
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1.1.5 Inhibition of cytochrome P450 
In addition to predicting the likelihood of some individuals being poor metabolizers due to a 
genetic deficiency in P450 expression, information on which human P450 enzyme metabolizes a 
drug can help predict or explain drug interactions (Pec93). 
Inhibitory drug interactions generally fall into three categories. The first involves competition 
between two drugs which are metabolized by the same P450 enzyme. For example, omeprazole 
and diazepam are both metabolized by CYP2C19. When the two drugs are administrated 
simultaneously, omeprazole decreases the plasma clearance of diazepam and prolongs its plasma 
half-life. The inhibition of diazepam metabolism by omeprazole is presumed to involve 
competition for metabolism by CYP2C19 because no such inhibition occurs in individuals who, 
for genetic reasons, lack this polymorphically expressed P450 enzyme. The second inhibitory 
drug interaction is also competitive in nature, but the inhibitor is not a substrate of the affected 
P450 enzyme. The inhibition of dextromethorphan biotransformation by quinidine is a good 
example of this type of drug interaction. Dextromethorphan is O-demethylated by CYP2D6, and 
the clearance of dextromethorphan is impaired in individuals lacking this polymorphically 
expressed enzyme. The clearance of dextromethorphan is similarly impaired when this 
antitussive agent is taken with quinidine, a potent inhibitor of CYP2D6. The third type of drug 
interaction results from noncompetitive inhibition of cytochrome P450, and it often involves so-
called mechanism-based inhibition (as in the case of grapefruit juice, which inhibits the 
presystemic elimination of a number of drugs and increases their bioavailability), or suicide 
inactivation of cytochrome P450 (Hal94), when the metabolites of some compounds bind to the 
heme and destruct it. The inhibition of terfenadine metabolism by macrolide antibiotics appears 
to be an example of this type of drug interaction. CYP3A4 converts macrolide antibiotics to a 
metabolite that binds so tightly (but noncovalently) to the heme moiety of CYP3A4 that it is not 
released from the enzyme’s active site. The noncompetitive inhibition of a P450 enzyme by a 
mechanism-based inhibitor can completely block the metabolism of a drug. As the fatal 
interaction between macrolide antibiotics and terfenadine indicates, noncompetitive inhibition of 
cytochrome P450 can have serious consequences. Numerous compounds are activated by 
cytochrome P450 to metabolites that bind covalently to the heme moiety or to the surrounding 
protein. These compounds, known as suicide inactivators, include various halogenated alkanes 
(CCl4), halogenated alkenes (vinyl chloride, trichloroethylene), allylic compounds 
(allylisopropylacetamide and secobarbital), and acetylenic compounds (ethinylestradiol and 
ethynylprogesterone, gestodene). Ethinyl derivatives of various P450 substrates have been 
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synthesized as potential selective mechanism-based inhibitors of individual P450 enzymes. For 
example, polycyclic aromatic hydrocarbons are preferred substrates of CYP1A1, and this 
enzyme can be activated by various ethinyl derivats of naphthalene and pyrene. 
 
4.2.2 Induction of cytochrome P450 
In contrast to inhibitors, inducers of cytochrome P450 increase the rate of xenobiotic 
biotransformation (Con67, Con82, Bat92). Clinically important consequences of P450 enzyme 
induction include the enhanced biotransformation of cyclosporin, warfarin, and contraceptive 
steroids by inducing the CYP3A4 and CYP2C enzymes, and enhanced activation of 
acetaminophen to its hepatotoxic metabolite, N-acetylbenzo-quinoneimine, by the CYP2E1 
inducers, ethanol and isoniazid, and possibly by CYP3A4 enzyme inducers. As an underlying 
cause of serious adverse effects, P450 induction is generally less important than P450 inhibition, 
because the latter can cause a rapid and large increase in the blood level of a drug, which can 
cause toxic effects and symptoms of drug overdose. In contrast, cytochrome P450 induction 
lowers blood levels, which compromises the therapeutic goal of drug therapy but does not cause 
an exaggerated response to the drug. An exception to this rule is the potentiating effect of alcohol 
and isoniazid on acetaminophen hepatotoxicity, which is in part because of cytochrome P450 
induction. 
 
4.2.3 Clinically relevant polymorphisms of NAT2 
The polymorphism in N-acetylation leads to the interindividual differences in the metabolism of 
drugs and xenobiotics which have a primary aromatic amine or a hydrazine structure. 
Genetically determined differences in NAT2 activity may play an important role in the treatment 
with NAT2 substrates. The frequency of side effects after use of drugs that are acetylated greatly 
differs in slow and rapid acetylators (Roo92): isoniazid hepatotoxicity (Tim77), sulfasalazine-
induced agranulocytosis (Wad00) and side effects during the treatment with co-trimoxazol 
(Zie98) were more frequent in slow acetylators. A significant association between isoniazid-
induced and rifampicin-induced hepatotoxicity and the NAT2 genotype was show by Ohno et al. 
(Ohn00). The relative risk, compared with that of the rapid type, was 4.0 (95% C. I., 1.94%-
6.06%) for the intermediate type and 28.0 (95% C. I., 26.0%-30.0%) for the slow type. Table 30 
presents the most common adverse effects of drugs metabolized by acetylation. 
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Table 30: Adverse effects of drugs – substrates of arylamine N-acetyltransferase 2 in 
relationship to the acetylator phenotype (according to Evans (Eva92)). 
Drug Indication Possible adverse effects Phenotype 
Aminoglutethimide Breast cancer Confusion, tiredness, vertigo, sickness, 
diarrhea, myelosuppression 
slow 
Amonafide Breast cancer Myelosuppression, confusion, tinnitus, 
vertigo, sickness 
slow 
Arrhythmia, gastrointestinal symptoms slow  Amrinone Heart failure 
thrombozytopenia rapid 
Dapsone Lepra Allergic skin reactions, 
methemoglobinemia, myelosuppression 
slow 
Peripheral neuropathy slow  Isoniazid Tuberculosis 
hepatotoxicity rapid 
Hydralazine Hypertension Lupoid syndrome slow 
Procainamide Tachyarrhythmia Lupoid syndrome, gastrointestinal 
symptoms, hypotension 
slow 
Sulfalene Malaria prophylaxis Allergic reactions, gastrointestinal 
symptoms, changes in the blood count, 
lupoid syndrome 
slow 
Sulfasalazine Rheumatoid 
arthritis, Crohn´s 
disease 
Vertigo, headache, reticulocytosis, 
gastrointestinal symptoms 
slow 
Sulfamethazine Infection, 
phenotyping 
Allergic symptoms slow 
 
NAT2 genotyping prior to medication may help discover patients who have a great risk of 
developing adverse side effects which are dependent on differences in the metabolism. 
 
4.2.4 Pharmacogenetic studies and the practice of medicine 
Hereditary polymorphisms in drug metabolizing enzymes and drug transporters determine the 
majority of adverse drug effects and drug ineffectiveness. It is to be expected that the increasing 
genetic knowledge will have considerable impact on disease management and healthcare in the 
future. It is already possible to identify sensitive individuals and to recommend individualized 
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genotype-dependent drug treatment, especially for drugs with a narrow therapeutic window. This 
allows to prevent adverse reactions already before drug treatment and thus substantially reduce 
the costs of therapy and hospitalization. 
The knowledge about the mechanism of drug action, the identification of new drug targets, and 
the understanding of genetic factors that affect drug response may allow to design drugs that are 
specifically targeted towards particular subgroups of the population or that avoid genetic 
variability in therapeutic response. 
 
4.3 The role of polymorphisms of drug metabolizing enzymes in the occurrence of 
some kinds of cancer 
Genetic differences in the regulation, expression and activity of phase I and phase II genes, 
encoding drug metabolizing enzymes might be crucial factors in defining cancer susceptibility, 
as well as in determining the toxic or carcinogenic potential of drugs and other environmental 
pollutants. 
Several epidemiological studies in cancer patients have shown that individual susceptibility to 
cancer might partly depend on the genetically determined high or low activity of certain 
enzymes. This association may be based on interindividual variation in the metabolism of 
carcinogens that are either detoxified, or metabolically activated to ultimate carcinogens. 
Cytochrome P450 2D6, glutathione S-transferase M, and N-acetyltransferase 2 have been 
primarily studied because of their well-known inheritable polymorphism and the availability of 
routine methods to determine an individual’s phenotypic expression. 
Research work has focused on two groups of classic environmental carcinogens: polycyclic 
aromatic hydrocarbons (PAH), generated from the combustion of fossil fuels, and aromatic 
amines, which are for example present in cigarette smoke. Both PAH and aromatic amines are 
major etiologic factors in lung, bladder, and possibly in breast cancers. Variations in the 
expression of the metabolic genes, such as the cytochrome P450, glutathione S-transferase 
(GST), and N-acetyltransferase (NAT) genes, strongly influence the individual biological 
response to carcinogens. The carcinogenic residues which bound to DNA or proteins, and which 
are known as adducts, provide both a fingerprint of exposure and an indicator of procarcinogenic 
DNA damage. In general, more PAH-DNA adducts are formed in smokers or in persons who are 
exposed to PAH at the workplace or in the ambient air. However, various studies have shown a  
30- to 50-fold interindividual difference in carcinogen-DNA binding under equivalent conditions 
of exposure (Per96). 
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A number of drug metabolizing enzyme superfamilies, including cytochrome P450 dependent 
monooxygenases, and other enzymes and receptor proteins have probably evolved as an adaptive 
response to environmental stimuli. Most drug metabolizing enzymes are primarily detoxifying 
enzymes, but CYP1A1, glutathione S-transferase T1 and sulfotransferase lead to an activation in 
the metabolism of polycyclic aromatic hydrocarbons, vicinal dihaloalkanes and methylated PAH 
oxides by catalyzing the generation of electrophilic metabolites. It is reasonable to assume that 
mutants or variant alleles which lead to an alteration in the activity of one of these enzymes 
would result in an altered susceptibility to chemically induced diseases, such as cancer and 
certain occupational diseases. 
The identification of susceptible populations could lead to the elucidation of mechanisms of 
disease and help to design the preventive strategies that are of the greatest benefit. 
 
 
4.3.1 Genetic polymorphism of CYP1A1 and cancer susceptibility 
The possible relationship between cytochrome P450 1A1, smoking, and lung cancer reveals the 
complex epidemiological background of environmentally induced disease. Some studies suggest 
an association between a particular CYP1A1 allele and smoking-induced lung cancer. However, 
the frequency of alleles varies markedly among different ethnic groups, so that extrapolation 
between populations is not justified. 
Allelic variant forms of CYP1A1 have been extensively studied in association with lung cancer 
susceptibility in a case-control epidemiology designs. The mutation m1 (3801T>C) was found to 
be overrepresented among lung cancer patients in Japan (Nak91). Studies in Caucasians could not 
confirm this finding (Tef91, Hir92b, Dra94), perhaps due to the lower allele frequency of 7.3% 
(Dra94) compared to 33.2% in Japanese (Nak91). The A>G transition at nucleotide 2455 (m2) is 
rare in Caucasians but occurs in about 20% of Japanese (Kaw93). The mutant enzyme showed 
enhanced activity. M2 was overrepresented in a Japanese study (Nak91) and also in a German 
study of lung cancer patients (Dra94), whereas only a trend was observed in a Finnish study 
(Hir92a). The mutation m4 (2453C>A) was shown not to represent a susceptibility factor for lung 
cancer (Cas96c). Hence, individuals with high CYP1A1 gene inducibility may be more 
susceptible to the carcinogens in tobacco smoke and they may be more likely to develop 
tobacco-related lung cancer. Genes other than CYP1A1 may also influence the incidence of 
cancer induced by smoking. Interactions of the recognized polymorphisms of CYP1A1 with other 
susceptibility polymorphisms in other genes (for example glutathione S-transferase M1 
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(GSTM1)) may be more relevant to lung carcinogenesis than any other polymorphism alone. The 
combination of phase I and phase II genotypes (example CYP1A1 Val/Val and GSTM1 null) has 
suggested possible susceptibility genotypes in the Japanese population, where odds ratios for 
lung cancer cases who displayed combined susceptible genotypes have ranged as high as 27 
(Nak93, Kih95), these combinations of genotypes are currently being explored in non-Asian 
populations. 
Genetic variation in receptors that are instrumental in the toxicokinetics of carcinogens can 
strongly influence cancer risk. Individuals with the high-affinity dioxin-binding aromatic 
hydrocarbon (Ah) receptor are likely to be at greater risk from dioxin and PAH, because by 
binding to the receptor, these chemicals up-regulate CYP1A1, CYP1A2, and other genes, thereby 
stimulating their own metabolism (Neb91). 
 
4.3.2 The influence of the CYP2D6 genotype on cancer susceptibility 
Studies of associations between the CYP2D6 polymorphism and susceptibility to specific 
diseases, particularly lung cancer, have produced conflicting results. The debrisoquine PM 
phenotype has been reported to be under-represented in smokers with lung carcinoma in 
comparison to noncancer controls (Aye84, Roo88, Law89, Cap90, Agu94, Bou96). A meta-analysis 
of the data published until 1992 reported an overall odds ratio of 2.3 of lung cancer patients 
displaying an intermediate or extensive metabolizer phenotype (Amo92). A Finnish study 
reported an odds ratio of 6.4 (p=0.05) in the EM phenotype in comparison to controls (Hir93). In 
a Spanish study, the CYP2D6*9 has been reported to be six times more frequent in lung cancer 
cases than in healthy controls (Agu94). However, a French group has reported no statistically 
significant relationship between this genotype and lung cancer status (Stu95), and there are 
several case-control studies that have found no relationship between debrisoquine phenotype 
prevalence and lung cancer (Ran95, Ben91, Duc91,  Stu95, Shaw95). One confounder appears to be 
the race; probably, the association seen in Caucasians cannot be extrapolated to Afro-Americans 
(Ing92) or Asians (Bert92). In summary, the data addressing the relationships between CYP2D6 
genotype, phenotype and lung cancer susceptibility remains conflicting and inconclusive. 
Brockmöller et al. (Bro96) investigated the role of different CYP2D6 alleles as susceptibility 
factors or protective factors in bladder cancer etiology; however, no association was found. 
It has been reported that persons with EM genotype of CYP2D6 and slow acetylator N-
acetyltransferase 2 (NAT2) genotype were at higher risk of developing hepatocellular carcinoma 
(Agu96). 
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4.3.3 The role of N-acetyltransferase 2 in the predisposition to aromatic and 
heterocyclic amine-induced carcinogenesis 
A number of aromatic amines such as 4-amino-biphenyl and heterocyclic amines such as 2-
amino-1-methyl-6-phenylimidazo pyridine are present in cigarette smoke (Man91) and in well-
done meat (Lay95). Aromatic and heterocyclic amine carcinogens require metabolic activation 
for DNA mutation and initiation of carcinogenesis. Following N-oxidation, the N-hydroxy-
aromatic and N-hydroxy-heterocyclic amines are further activated by N-acetyltransferases to 
their ultimate carcinogenic forms (Hei88, Hei95). Both NAT1 and NAT2 catalyze the metabolic 
activation of aromatic and heterocyclic amine carcinogens (Min92, Hei93, Hei95). Thus, genetic 
polymorphisms in NAT1 and NAT2 may affect the metabolic activation of aromatic and 
heterocyclic amine carcinogens and modify cancer risk. Epidemiological studies investigating 
the role of NAT1 and NAT2 polymorphisms in colorectal cancer illustrate the complexity of the 
etiologic background. The current mechanistic hypothesis suggests that rapid NAT1 and NAT2 
acetylators should more readily activate N-hydroxy-heterocyclic amine carcinogens to their 
ultimate carcinogenic forms; therefore, these individuals are predisposed to colorectal cancer. 
However, human populations are genetically heterogeneous and exposures to heterocyclic 
amines are difficult to estimate. Therefore, it is not surprising that the results of studies which 
tried to verify the hypothesis are not consistent: while several investigations (Lan86, Ile87, Gil98) 
found an association between the rapid NAT2 acetylator phenotype and colorectal cancer, other 
studies (Lad91, Rod93, Shi94, Pro95, Spu95, Hub97) did not. Five studies (Lan94, Rob96, Wel97, 
Che98, Kam99) found associations between the rapid NAT2 acetylator phenotype and colorectal 
cancer primarily in individuals who consumed well-done meat, and, presumably were exposed to 
larger quantities of heterocyclic amine carcinogens (Sko95). One study found that the association 
was confined to homozygous rapid acetylators (Gil98), a finding also observed for lung cancers 
(Cas96b) and laryngeal (Hen99) cancers. Bell et al. (Bel95) found an association between the 
NAT1*10 allele and colorectal cancer; the risk was highest in NAT2 rapid acetylators. Another 
study also showed a higher risk for colorectal cancer in individuals who consumed well-done 
meat and possessed both the NAT1*10 allele and a rapid acetylator NAT2 genotype (Che98). 
NAT1*10 and NAT2*4 (the most common rapid acetylator NAT2 allele) are in a linkage 
disequilibrium (Sme98, Hen99) which may be a factor in the association of the NAT1*10 allele 
with colorectal cancer. However, two studies reported a lack of association between the 
NAT1*10 allele and colorectal cancer (Pro96, Lin88). 
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Recently investigations have examined the possible relationship between NAT1 and NAT2 
acetylation polymorphisms and breast cancer risk. Zheng et al. (Zhe99) observed an association 
of the NAT1*11 allele with breast cancer, particularly in women who smoked or consumed their 
meat very well done. In another study, an association between the rapid/intermediate NAT2 
acetylator phenotype and breast cancer was found in women who consumed well-done meat 
(Dei00). Many other investigations, which have been published recently, suggest that the 
acetylation polymorphism is a factor in genetic predisposition to cancers of different types 
especially when linked to aromatic and heterocyclic amine carcinogen exposures. 
 
4.3.4 Cancer susceptibility related to ethnicity or race 
Epidemiological data shows that ethnic and racial groups differ significantly in terms of cancer 
incidence and mortality rates (Zah95). Cancer incidence rates of esophageal cancer in black 
Americans are approximately three times higher than in white Americans; incidence rates of 
multiple myeloma, liver, cervical, and stomach cancer are twice as high; and those of cancers of 
the oral cavity and pharynx, larynx, lung, prostate, and pancreas are 50% higher. The incidence 
of chronic lymphocytic leukemia, multiple myeloma, and premenopausal breast cancer is also 
higher in black Americans. In contrast, white Americans have higher incidence rates of 
melanoma, leukemia, lymphoma, and cancers of the endometrium, thyroid, bladder (in males), 
ovary, testis, and brain, as well as postmenopausal breast cancer (ACS97). In Hispanics cancer 
rates are generally lower than in white or black Americans, but rates differ substantially among 
Hispanics of different race (Per96). 
Among the biologic factors that might contribute to the higher cancer risks in certain ethnic or 
racial groups are variations in the prevalence of genetic traits affecting carcinogen metabolism 
and DNA repair. The stronger association between the serum concentration of the DDT 
metabolite DDE and breast cancer in black women relative to white women may reflect genetic 
differences affecting the induction of the enzyme-mediated estrogen metabolism by chlorinated 
hydrocarbons (Mil95). The GSTM1 null genotype occurs less frequently in Blacks (35%) than in 
Whites (49%) (Bel93). The NAT2 slow acetylator phenotype occurs in about 59% of Whites 
(Cas95), in 55% of Blacks (Del96), and in 14% of Asians (Yu94), these frequencies are consistent 
with the respective ethnic or racial differences in bladder cancer rates. 
Racial or ethnic variation in cancer risk may reflect differences in environmental exposure or 
socioeconomic and demographic factors as well as in hereditary biologic susceptibility. The rise 
in breast cancer rates experienced by the descendants of Asian immigrants to the United States 
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provides strong evidence that environmental factors affect cancer patterns. After several 
generations, the rates in Asian Americans are the same as those of the U.S. white population 
(Zah95, Mil95). Within the United States, substantial ethnic or racial variations in the extent of 
environmental exposure to certain pollutants have also been recorded (Per96). 
 
 
5 Summary 
The basic principle of drug and xenobiotic metabolism in the body is to make them more water 
soluble and thus more readily excreted in the urine. Drug and xenobiotic transformation 
reactions are divided into two groups, namely phase I and phase II. Various drug metabolizing 
enzymes of phases I and II are subject to genetic polymorphism. The activity of these enzymes 
can vary from zero to high. Genetic polymorphisms are known to contribute considerably to 
interindividual variations in the metabolism of numerous drugs and xenobiotics. The phase I 
enzymes of the cytochrome P450 family (CYP450) are the most important enzymes in drug and 
xenobiotics metabolism. Among the human CYP isoforms, CYP2D6 seems to be one of the most 
relevant. It catalyzes the metabolism of nearly 25% of all clinically important drugs, such as 
antiarrhythmic drugs, tricyclic antidepressants, beta-blockers and others. The CYP1A1 enzyme 
is responsible for the oxidative metabolism of toxicants such as dioxin and benzo(a)pyrene. The 
phase II metabolizing enzyme arylamine N-acetyltransferase 2 (NAT2) plays an important role 
in the biotransformation of a number of aromatic and heterocyclic amines and hydrazines, which 
are contained in various drugs and in environment. Genetic polymorphisms of drug metabolizing 
enzymes are responsible for altered enzyme level and activity and associated with altered risk of 
adverse drug reactions and some cancers. 
The allele frequency of genes, encoding phase I and phase II enzymes has been described for a 
number of populations and revealed a wide ethnical variation. However, this are no data 
available about the polymorphisms of drug metabolizing enzymes in the Russian population, 
which is the biggest Slavic one. That is why we investigated the genotypes of some of the genes, 
encoding drug and xenobiotic metabolizing enzymes of phases I and II and compared our results 
with the corresponding data from other populations. In this way we wanted to classify whether 
Russians are genetically similar to other Caucasian groups or whether there is some Asian 
influence. 
In this study we investigated 325 individuals of Russian origin, who were healthy volunteers or 
patients without malignant diseases. Our study included the complete investigation of two 
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enzymes of phase I, CYP1A1 and CYP2D6, and one phase II enzyme, NAT2. We determined all 
known mutations of CYP1A1: m1 (3801T>C), m2 (2455A>G), m3 (3205T>C), m4 (2453C>A), 
m5 (-4335G>A), and the novel m6 (-3219C>T) and m7 (-3229G>A) mutations. We screened for 
the  functionally important alleles *1,*3, *4, *5, *6, *10 of the CYP2D6 gene and for gene 
duplications, which is sufficient to predict a metabolizing phenotype in 95-99% of individuals 
(Sac97). We checked on the most common NAT2 point mutations: 191G>A, 282C>T, 341T>C, 
481C>T, 590G>A, 803A>G, 857G>A, and the novel 111T>C mutation. 
In addition to conventional PCR-RFLP genotyping of NAT2 polymorphisms, 127 samples were 
analyzed using a novel LightCycler method. For this method we optimized a number of reactions 
with hybridization probes. This assay provides a basis for the rapid detection of the NAT2 
genotype in large-scale studies or routine genotyping in the laboratory. 
The mutations m1 (3801T>C), m2 (2455A>G), m4 (2453C>A), m5 (-4335G>A), m6 (-
3219C>T), and m7 (-3229G>A) of CYP1A1 occurred in 9.8% (95% confidence interval, 7.7%-
12.4%), 5.0% (95% C. I., 3.5%-7.1%), 2.5% (1.4%-4.0%), 25.8% (22.5%-29.4%), 6.0% (4.3%-
8.1%), and 2.9% (1.8%-4.5%) of alleles, respectively. The frequencies of m1, m2 and m4 were 
similar to those in other European groups, but differed statistically significantly from those in a 
Turkish sample (p=0.0004 for m1 mutation, p=0.04 for m2 mutation and p=0.007 for m4 
mutation (Ayn98)) and in a Japanese sample (p<0.0001 for m1 mutation (Nak91)). Mutation m2 
was found to be strictly linked with m1, forming allele CYP1A1*2B. We did not find the m3 
mutation, which has only been detected in Africans up to now. The frequencies of the CYP1A1 
high-activity alleles, CYP1A1*2A and CYP1A1*2B, were 4.6% (3.1%-6.5%) and 5.1% (3.5%-
7.1%), respectively. 
5.9% (3.5%-9.2%) of all subjects were CYP2D6 poor metabolizers, whereas 3.4% (1.7%-6.3%) 
were identified as ultra-rapid metabolizers (CYP2D6*1x1/*1). The mutation spectrum in 
CYP2D6 and the proportion of intermediate and extensive metabolizers in Russians (34.2%, and 
57.9%, respectively) were similar to those of other Caucasians. 
Genotyping eight different single nucleotide polymorphisms in the NAT2 gene provided a 
genotype associated with slow acetylation in 59.7% (54.1%-65.1%) of individuals, 34.7% 
(29.6%-40.2%) of participants carried at least one allele encoding rapid acetylation, and 5.6% 
(3.3%-8.6%) were homozygous for the rapid-acetylation allele (wild-type allele *4 or mutant 
allele *12A). The frequencies of the point mutations, alleles and genotypes of NAT2 of the 
Russian sample were similar to those of other Caucasians. As in other European groups, the 
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prevalence of slow acetylators in Russians appeared to be due to the high frequency of *5 alleles. 
The Black-specific 191G>A was not detected in our sample. 
As the fluorescence genotyping of six polymorphisms of NAT2, using LightCycler, correlated in 
all samples with previously validated genotyping by restriction enzyme digestion (PCR-RFLP),  
we can recommend this method as a reliable, fast and easy way of  NAT2 genotyping. 
The complete overview of allele distribution of the most important drug and xenobiotic 
metabolizing enzymes among Russians shows that the allele frequency is similar to that of other 
Caucasians. We did not identify any Asian influence in our Russian sample. No specific African 
genetic traits were detected in our sample. Therefore it may be expected that drug side effects 
and efficacy problems due to an individual’s genetic background are similar compared to those 
in other European populations. 
This comprehensive set of data should give a basis for clinical studies on drug disposition in the 
Russian population and further investigations of the role of polymorphic enzymes in the 
development of different kinds of cancer. Individual therapy recommendations for drugs 
metabolized by polymorphic drug metabolizing enzymes should be introduced into clinical 
practice to adjust the individual doses to genotype, determine the appropriate dosage of certain 
drugs and thus prevent therapeutic failures, adverse effects and toxicity. 
 
 
6 Zusammenfassung 
Die Umwandlung in wasserlösliche Verbindungen, die renal ausgeschieden werden können, ist 
ein grundlegendes Prinzip im Abbau von Fremdstoffen. Hierbei unterscheidet man Phase-I- und 
Phase-II-Reaktionen. Die Aktivität vieler Phase-I- und Phase-II-Enzyme ist genetisch beeinflusst 
und kann weniger und stärker ausgeprägt sein. Genetische Polymorphismen sind für die starken 
interindividuellen Unterschiede im Metabolismus von Fremdstoffen verantwortlich. Die Phase-I-
Enzyme der Cytochrom-P450-Familie sind für den Abbau der meisten Arzneimittel sowie 
toxischen Fremdstoffen essentiell. Von den CYP-Isoenzymen ist CYP2D6 am Abbau von 
nahezu 25% aller klinisch eingesetzten Arzneistoffe (z.B. Antiarrhythmika, Antidepressiva, 
Beta-Blocker) beteiligt. Das CYP1A1-Enzym abbaut Toxine wie Dioxin und Benzo(a)pyren. 
Das Phase-II-Enzym Arylamin-N-Acetyltransferase 2 (NAT2) spielt eine wichtige Rolle in der 
Biotransformation von aromatischen und heterozyklischen Aminen und Hydrazinen, die als 
Medikamente und in der Umwelt vorkommen. Genetische Polymorphismen der Enzyme des 
Fremdstoffmetabolismus sind für eine veränderte Expression und Aktivität der betroffenen 
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Genprodukte verantwortlich und können das Krebsrisiko und das Risiko für 
Arzneimittelnebenwirkungen beeinflussen. 
Die Häufigkeitsverteilungen der Allele der Gene, die Phase-I- und Phase-II-Enzyme kodieren, 
sind für viele Populationen bekannt; sie zeigen eine große interethnische Varianz. Da die 
Polymorphismen dieser Enzyme bisher jedoch noch nicht in der größten slawischen 
Volksgruppe, der russischen, untersucht wurden, haben wir die Häufigkeitsverteilungen 
verschiedener Genvarianten analysiert und unsere Ergebnisse mit den entsprechenden Daten 
anderer Populationen verglichen mit dem Ziel, Ähnlichkeiten oder Unterschiede zu anderen 
kaukasischen bzw. zu  asiatischen Bevölkerungsgruppen aufzuzeigen. 
An der vorliegenden Studie nahm eine Gruppe von 325 Personen russischer Abstammung teil - 
gesunde Probanden bzw. Patienten, die nicht an einer malignen Erkrankung litten. Die 
Polymorphismen von zwei Enzymen der Phase I, CYP1A1 und CYP2D6, und von einem Enzym 
der Phase II, NAT2, wurden komplett untersucht. Wir bestimmten alle bekannten Mutationen 
von CYP1A1 - m1 (3801 T>C), m2 (2455A>G), m3 (3205T>C), m4 (2453C>A), m5 (-
4335G>A) - sowie die erst vor kurzem entdeckten Varianten m6 (-3219C>T) und m7 (-
3229G>A). Die funktionell bedeutsamsten Allele des CYP2D6-Gens (*1,*3, *4, *5, *6, *10) 
sowie die Genduplikationen, die für die Erkennung des Phänotyps in 95-99% der Fälle 
ausreichen (Sac97), wurden bestimmt. Wir überprüften die häufigsten NAT2 Punktmutationen - 
191G>A, 282C>T, 341T>C, 481C>T, 590G>A, 803A>G, 857G>A - und die kürzlich entdeckte 
111T>C Mutation. 
Zusätzlich zur konventionellen PCR-RFLP-Genotypisierung des NAT2 Polymorphismus 
analysierten wir 127 Proben mit der LightCycler-Hyprobe Methode. Real-time-PCR-Verfahren, 
wie die von uns eingesetzte LightCycler-Technologie, ermöglichen eine zuverlässige 
Genotypisierung in kürzester Zeit. Dies vereinfacht die Durchführung pharmakogenetischer 
Studien oder Routineuntersuchungen im Labor erheblich. 
Die Häufigkeiten der genetischen Varianten von CYP1A1 waren: m1 (3801T>C) - 9,8% (95% 
Vertrauensbereich, 7,7%-12,4%), m2 (2455A>G) - 5,0% (95% VB, 3,5%-7,1%), m4 (2453C>A) 
- 2,5% (1,4%-4,0%), m5 (-4335G>A) - 25,8% (22,5%-29,4%), m6 (-3219C>T) - 6,0% (4,3%-
8,1%), und m7 (-3229G>A) - 2,9% (1,8%-4,5%). Die Häufigkeitsverteilung von m1, m2 und m4 
ähnelt anderen Europäern, unterscheidet sich aber signifikant von den Ergebnissen einer 
türkischen (p=0,0004 für Mutation m1, p=0,04 für Mutation m2 und p=0,007 für Mutation m4 
(Ayn98))  und einer japanischen Studie (p<0,0001 für Mutation m1 (Nak91)). Die Mutationen m2 
und m1 lagen gekoppelt vor („linkage“) und bildeten das Allel CYP1A1*2B. Die Mutation m3, 
die bisher nur bei Afrikaner gefunden wurde, konnten wir nicht nachweisen. Die Häufigkeit der 
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CYP1A1 Allele mit hoher Aktivität, CYP1A1*2A und CYP1A1*2B, betrug 4,6% (3,1%-6,5%) 
bzw. 5,1% (3,5%-7,1%). 
5,9% (3,5%-9,2%) aller Probanden waren CYP2D6 Langsam-Metabolisierer und 3,4% (1,7%-
6,3%) wurden als Ultraschnell-Metabolisierer identifiziert (CYP2D6*1x1/*1). Das 
Mutationsspektrum von CYP2D6 und das Verhältnis von intermediären und schnellen 
Metabolisierer in der russischen Stichprobe zeigten Gemeinsamkeiten mit anderen Studien an 
Kaukasiern. 
Bei der Genotypisierung von acht verschiedenen Punktmutationen im NAT2-Gen ergab sich für 
59,7% (54,1%-65,1%) der Studienteilnehmer ein Genotyp, der mit einer Langsam-Acetylierer-
Status einhergeht. 34,7% (29,6%-40,2%) der Probanden hatten ein und 5,6% (3,3%-8,6%) zwei 
für die Schnellacetylierung kodierende Allele. Die Häufigkeitsverteilung der Punktmutationen, 
Allele und Genotypen des NAT2-Gens in diesem russischen Kollektiv zeigte viele 
Übereinstimmungen mit anderen kaukasischen Bevölkerungsgruppen. Wie bei anderen 
Europäern überwiegen auch in der russischen Bevölkerung aufgrund der Häufigkeit des Alleles 
*5 die Langsam-Acetylierer. Die für Afrikaner spezifische Variante 191G>A wurde nicht 
gefunden. 
Die auf fluoreszenzmarkierten Sonden basierende Methode zur Genotypisierung der sechs 
Polymorphismen des NAT2-Gens mittels LightCyclers stimmte mit der konventionellen 
Bestimmung per PCR-RFLP in allen untersuchten Proben überein. Damit wurde das 
LightCycler-Verfahren als zuverlässige, schnelle und einfache Methode zur NAT2-
Genotypisierung validiert. 
Die Allelverteilung der für die wichtigsten Enzyme im Arzneimittelstoffwechsel kodierenden 
Gene ist bei Russen ähnlich wie bei anderen Kaukasiern. Es wurden weder asiatischer Einfluss 
gefunden noch die für Afrikaner charakteristischen Besonderheiten. Es kann deshalb erwartet 
werden, dass die genetisch-bedingten Unterschiede in der Wirksamkeit und im Auftreten von 
Arzneimittelnebenwirkungen in der russischen Bevölkerung vergleichbar sind mit denen in 
anderen europäischen Populationen. 
Die von uns gesammelten populationsgenetischen Daten stellen eine wichtige Grundlage für 
weitere klinische Studien in der russischen Bevölkerung zum Einfluss genetischer Varianz auf 
die Arzneimittelverträglichkeit und die Rolle polymorpher arzneistoffmetabolisierenden Enzyme 
in der Pathogenese verschiedener Krebserkrankungen dar. 
Die Genotypisierung von Enzympolymorphismen ermöglicht es, die Arzneimitteldosierung auf 
der Grundlage pharmakogenetischer Daten individuell anzupassen und damit das Risiko für 
unerwünschte Arzneimittelwirkungen oder Therapieversagen zu reduzieren. 
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